Original Article
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
N Engl J Med 2004; 350:1200-1210March 18, 2004
- Abstract
Background
The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results.
Methods
In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment with chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients to chemotherapy alone (fluorouracil), 72 patients to both chemoradiotherapy and chemotherapy, and 69 patients to observation.
Results
The analysis was based on 237 deaths among the 289 patients (82 percent) and a median follow-up of 47 months (interquartile range, 33 to 62). The estimated five-year survival rate was 10 percent among patients assigned to receive chemoradiotherapy and 20 percent among patients who did not receive chemoradiotherapy (P=0.05). The five-year survival rate was 21 percent among patients who received chemotherapy and 8 percent among patients who did not receive chemotherapy (P=0.009). The benefit of chemotherapy persisted after adjustment for major prognostic factors.
Conclusions
Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival.
Media in This Article
Figure 1
The Two-by-Two Randomization Procedure Used for Both Chemoradiotherapy and Chemotherapy.Figure 2
Kaplan–Meier Estimates of Survival According to Whether or Not Patients Received Chemoradiotherapy (Panel A) or Chemotherapy (Panel B).Article Activity
- Article
Pancreatic cancer, with an overall five-year survival rate ranging from 0.4 percent1 to 4 percent,2 has a poor prognosis and is one of the top 10 causes of death from cancer in the Western world.3,4 Surgical resection improves the outlook, although only about 10 percent of patients with pancreatic cancer are eligible for the procedure.5-9 Most treatment failures are due to local recurrence, hepatic metastases, or both and occur within one to two years after surgery.10-12
Adjuvant (postoperative) therapy may improve long-term survival,7-9,13-16 but its routine use is not universal8 because the results of randomized trials have been inconclusive.13 The Gastrointestinal Tumor Study Group (GITSG) randomly assigned 43 patients to receive surgery alone or chemoradiotherapy followed by maintenance chemotherapy.14,15 The median survival was significantly longer in the adjuvant-treatment group than in the surgery group (20 months vs. 11 months), with 5-year survival estimates of 18 percent and 8 percent, respectively.14,15 Three subsequent randomized studies, however, failed to confirm the benefit of adjuvant treatment.17-19 Moreover, it is unclear whether the survival advantage in the GITSG trial was due to the combination of chemoradiotherapy and maintenance chemotherapy or to only one of these treatments.13
The European Study Group for Pancreatic Cancer (ESPAC) undertook a large, multicenter trial to investigate the possible benefits of adjuvant chemoradiotherapy and maintenance chemotherapy in patients with pancreatic cancer. Although preliminary data indicated a survival benefit for adjuvant chemotherapy, the results were inconclusive owing to the short follow-up of only 10 months.20,21 In this report we summarize the results of this trial after it reached the primary end point and a median follow-up of 47 months among surviving patients.20,21
Methods
Patients and Trial Design
The ESPAC-1 trial used a two-by-two factorial design in which, after resection of the pancreatic ductal adenocarcinoma, each patient was randomly assigned to receive chemoradiotherapy or chemotherapy, neither treatment, or both treatments (Figure 1Figure 1
The Two-by-Two Randomization Procedure Used for Both Chemoradiotherapy and Chemotherapy.). The goal was to enroll 70 patients in each of the four groups, yielding combined data for 140 patients in each group for the two main treatment comparisons (chemoradiotherapy vs. no chemoradiotherapy and chemotherapy vs. no chemotherapy) and giving the study the ability to detect absolute differences in the mortality rate at two years of more than 20 percent at a significance level of 5 percent with 90 percent power. The trial was approved by the ethics committees at the national and local level according to the requirements of each country, and all participants gave written informed consent.Patients who had undergone a complete macroscopic resection22 of histologically proven pancreatic ductal adenocarcinoma underwent randomization with the use of a blocked method. They were stratified according to the randomization center (the United Kingdom, Switzerland, Germany, or France) and the status of the resection margin (positive or negative). Patients were followed up at three-month intervals until death. A subgroup of patients completed questionnaires about their quality of life.23
Adjuvant Therapy
Chemoradiotherapy consisted of a 20-Gy dose to the tumor given in 10 daily fractions over a two-week period plus an intravenous bolus of fluorouracil (500 mg per square meter of body-surface area on each of the first three days of radiotherapy and again after a planned break of two weeks). Chemotherapy consisted of an intravenous bolus of leucovorin (20 mg per square meter), followed by an intravenous bolus of fluorouracil (425 mg per square meter) on each of 5 consecutive days every 28 days for six cycles. Combination therapy consisted of chemoradiotherapy followed by chemotherapy, both administered as described above.
Adverse effects were assessed with the use of the Common Toxicity Criteria24 and a clearly defined protocol for modifications and delays of treatment. The study required each center to treat patients according to its own quality-assurance standards for radiotherapy.
Statistical Analysis
The primary outcome measure was the two-year survival rate; secondary outcomes were the incidence of adverse effects and recurrence and measures of the quality of life. Survival was calculated from the date of resection until the date of death from any cause; for patients lost to follow-up, data were censored on the date the patient was last seen alive. Survival estimates were derived by the method of Kaplan and Meier,25 and the log-rank test26 was used to assess differences in survival estimates among the groups. Stratified log-rank analyses and Cox proportional-hazards modeling27 were used to investigate and adjust for major prognostic and stratification factors. Hazard ratios indicating the effects of treatment on the risk of death were calculated and displayed in Forrest plots.28 Standardized area-under-the-curve methods29 were used to assess the mean observed quality of life within 12 months after resection; the global quality of life was compared among the groups with the use of the nonparametric Wilcoxon two-sample test. All analyses were carried out according to the intention-to-treat principle, and all reported P values are two-sided.
Results
A total of 289 patients from 53 hospitals in 11 European countries underwent randomization between February 1994 and June 2000. Three ineligible patients (one who had not undergone resection and two who had previously had breast cancer) were included in the analysis on an intention-to-treat basis. Clinical features and characteristics of the tumors were similar among the groups (Table 1Table 1
Characteristics of the Patients.). The median time from resection to randomization was 21 days (interquartile range, 14 to 35), and the median time from resection to the start of assigned treatment was 46 days (interquartile range, 34 to 67) for the patients assigned to chemotherapy and 61 days (interquartile range, 47 to 80) for the patients assigned to chemoradiotherapy.Compliance and Adverse Effects
A total of 145 patients were assigned to receive chemoradiotherapy (alone or with adjuvant chemotherapy), and 144 were assigned not to receive chemoradiotherapy — they received chemotherapy alone or were observed — according to the two-by-two design (Figure 1). Treatment details were available for 128 of the 145 patients who received chemoradiotherapy (88 percent), of whom 90 (70 percent) received a total of 40 Gy according to the protocol, 27 (21 percent) received either more or less than 40 Gy, and 11 (9 percent) did not receive any chemoradiotherapy; most protocol violations were due to the patient's decision not to receive the randomly assigned treatment (50 percent) or to progressive disease (19 percent).
A total of 147 patients were assigned to chemotherapy (75 to chemotherapy alone and 72 to chemotherapy in combination with chemoradiotherapy), and 142 did not receive chemotherapy alone (69 were assigned to the observation group and 73 to the chemoradiotherapy group), according to the two-by-two design (Figure 1). Treatment details were available for 122 of the 147 patients randomly assigned to receive chemotherapy (83 percent), of whom 61 (50 percent) received six cycles according to the protocol, 40 (33 percent) received fewer than six cycles, and 21 (17 percent) did not receive any chemotherapy; most protocol violations in this block were due to the patient's decision not to receive chemotherapy (33 percent) or to progressive disease (38 percent). Patients with a protocol violation were included in the analysis in their randomly assigned treatment group on an intention-to-treat basis.
Clinicians were asked to record the most severe episode of myelotoxic effects, stomatitis, diarrhea, and other adverse events. Adverse events of grade 3 or 4 were reported in 29 patients: 7 had hematologic events (2 patients assigned to chemotherapy alone and 5 to combination therapy), 9 had stomatitis (4 patients assigned to chemotherapy alone and 5 to combination treatment), 6 had diarrhea (2 patients assigned to chemotherapy alone and 4 to combination treatment), and 7 had other types of adverse events (2 patients assigned to chemoradiotherapy alone, 3 to chemotherapy alone, and 2 to combination treatment).
Survival
The analysis of survival was based on 237 deaths among the 289 patients (82 percent). The duration of follow-up was similar among the groups; the median was 47 months (interquartile range, 33 to 62) for the 52 patients who were still alive at the time of the analysis. All but 12 deaths were disease-related: there were 2 treatment-related deaths (1 associated with chemoradiotherapy alone and 1 with combination treatment), 1 death from colon cancer, 1 from ovarian cancer, 3 from pulmonary embolism, 1 from myocardial infarction, 2 from a ruptured aortic aneurysm, 1 from gastrointestinal bleeding, and 1 from unknown causes. Survival was calculated from the date of resection. A sensitivity analysis in which survival was calculated from the date of randomization did not change the interpretation of the results or the conclusions.
Chemoradiotherapy
The median survival was 15.9 months (95 percent confidence interval, 13.7 to 19.9) among the 145 patients who were assigned to chemoradiotherapy and 17.9 months (95 percent confidence interval, 14.8 to 23.6) among the 144 patients who were not assigned to receive chemoradiotherapy (hazard ratio for death, 1.28; 95 percent confidence interval, 0.99 to 1.66; P=0.05). Two-year and five-year survival estimates were 29 percent and 10 percent, respectively, among patients who received chemoradiotherapy and 41 percent and 20 percent, respectively, among those who did not receive chemoradiotherapy (Figure 2AFigure 2
Kaplan–Meier Estimates of Survival According to Whether or Not Patients Received Chemoradiotherapy (Panel A) or Chemotherapy (Panel B).). The Forrest plot (Figure 3Figure 3
Forrest Plot of the Effect of Chemoradiotherapy on the Hazard Ratio for Death.) confirmed the lack of a statistically significant benefit of chemoradiotherapy whether or not patients were also randomly assigned to receive additional chemotherapy.Chemotherapy
The median survival was 20.1 months (95 percent confidence interval, 16.5 to 22.7) among the 147 patients who received chemotherapy and 15.5 months (95 percent confidence interval, 13.0 to 17.7) among the 142 patients who did not receive chemotherapy (hazard ratio for death, 0.71; 95 percent confidence interval, 0.55 to 0.92; P=0.009). Two-year and five-year survival estimates were 40 percent and 21 percent, respectively, among patients who received chemotherapy and 30 percent and 8 percent, respectively, among patients who received no chemotherapy (Figure 2B). The Forrest plot (Figure 4Figure 4
Forrest Plot of the Effect of Chemotherapy on the Hazard Ratio for Death.) confirmed a significant survival benefit for chemotherapy whether or not patients were also randomly assigned to receive chemoradiotherapy.Additional Survival Analyses
The median survival was 16.9 months (95 percent confidence interval, 12.3 to 24.8) among the 69 patients randomly assigned to observation, 13.9 months (95 percent confidence interval, 12.2 to 17.3) among the 73 patients randomly assigned to chemoradiotherapy, 21.6 months (95 percent confidence interval, 13.5 to 27.3) among the 75 patients randomly assigned to chemotherapy, and 19.9 months (95 percent confidence interval, 14.2 to 22.5) among the 72 patients randomly assigned to chemoradiotherapy plus chemotherapy. The respective five-year survival estimates were 11 percent, 7 percent, 29 percent, and 13 percent. This two-by-two trial did not have the statistical power to compare these four groups directly.
Influence of Prognostic Factors
Log-rank analysis of the characteristics of patients and tumors revealed no significant differences in survival with respect to sex; an age of 60 years or more, as compared with less than 60 years; and the presence of preoperative diabetes, local invasion at operation, and postoperative complications, but borderline effects were found for current smoking (P=0.07), positive resection margins (P=0.10), and the presence of involved adjacent structures on histologic analysis (P=0.10). Increasingly differentiated tumors (P<0.001), the presence of lymph-node involvement (P<0.001), and a maximal tumor size of more than 2 cm, as compared with 2 cm or less (P=0.003), had significant adverse influences on survival. Stratifying treatment effects according to each of these factors did not influence the overall treatment result.
Cox regression modeling identified the grade of disease, tumor size (retained as a continuous variable), and lymph-node status as independent prognostic factors, adjusted for two stratification factors at randomization: randomization center (United Kingdom, Switzerland, Germany, or France) and resection-margin status (negative or positive) (Table 2Table 2
Cox Regression Model of the Effect of Chemoradiotherapy and Chemotherapy, Adjusted for Prognostic and Stratification Factors.). The analysis confirmed an adjusted hazard ratio for death of 1.47 (95 percent confidence interval, 1.10 to 1.95) with the use of chemoradiotherapy and an adjusted hazard ratio for death of 0.77 (95 percent confidence interval, 0.58 to 1.01) with the use of chemotherapy (Table 2). The interaction between chemotherapy and chemoradiotherapy in patients who underwent randomization according to the two-by-two design was tested with the use of a formal log-rank test and a multiplication interaction term, and the results of both were nonsignificant.Recurrence
Of 158 patients who were known to have had a tumor recurrence, local recurrence alone was reported in 56 (35 percent), distant metastases alone in 53 (34 percent), and both types in 43 (27 percent); the site of recurrence was unknown in 6 patients (4 percent). Known recurrences were identified in 84 of 102 patients who were assigned to chemoradiotherapy (82 percent) and in 74 of 106 patients who did not receive chemoradiotherapy (70 percent). The median time to recurrence was 10.7 months (95 percent confidence interval, 8.8 to 15.5) among patients who received chemoradiotherapy and 15.2 months (95 percent confidence interval, 9.8 to 22.2) among those who did not receive chemoradiotherapy (P=0.04), with estimated 12-month recurrence-free survival rates of 46 percent and 55 percent, respectively. The disease recurred in 79 of 110 patients who received chemotherapy (72 percent) and in 79 of 98 patients who did not receive chemotherapy (81 percent). The median time to recurrence was 15.3 months (95 percent confidence interval, 10.5 to 19.2) among patients given chemotherapy and 9.4 months (95 percent confidence interval, 8.4 to 15.2) among patients who were not given chemotherapy (P=0.02), with estimated 12-month recurrence-free survival rates of 58 percent and 43 percent, respectively.
Quality of Life
Questionnaires regarding the quality of life were completed by 152 of the 289 patients (53 percent), a representative sample of the main study group. There were no significant differences in the mean observed quality of life within 12 months after resection between patients who received chemotherapy and those who did not receive chemotherapy (P=0.75) or between patients who received chemoradiotherapy and those who did not receive chemoradiotherapy (P=0.17).
Discussion
The results of the ESPAC-1 trial, which was a large, adequately powered, randomized trial of adjuvant treatment for resectable pancreatic cancer, show a significant survival benefit for adjuvant chemotherapy. The effect of adjuvant chemotherapy is particularly encouraging, since 18 percent of the patients had positive resection margins, a criterion for exclusion in the GITSG trial.14,15 Our results also show that adjuvant chemoradiotherapy not only fails to benefit patients but also reduces survival when it is given before chemotherapy.
The European Organization for Research and Treatment of Cancer (EORTC) randomly assigned 218 patients with pancreatic or ampullary tumors to adjuvant chemoradiotherapy (but no maintenance chemotherapy) or surgery alone.17 There was no significant difference in survival between the groups, including the 114 patients with pancreatic cancer, with median survivals of 17 and 13 months in the treatment and observation groups, respectively, and with 5-year survival estimates of 23 percent and 10 percent, respectively.17 Even apart from the high dropout rate, however, the study was statistically underpowered. A Norwegian study randomly assigned 61 patients (14 with ampullary tumors) to adjuvant chemotherapy (doxorubicin, mitomycin, and fluorouracil) or surgery alone.18 The median survival was significantly longer in the adjuvant-treatment group than in the observation group (23 months vs. 11 months), but the 5-year survival rate was not (4 percent vs. 8 percent).18 This trial was also statistically underpowered, and the results discouraged further use of the doxorubicin-containing regimen because of its toxicity.18 A Japanese trial reported no benefit from adjuvant chemotherapy, but its design precluded definitive conclusions from being drawn.19
Evidence that adjuvant chemoradiotherapy for pancreatic cancer improves local control is inconclusive,30-32 and better local control has not been shown to correlate with increased survival.14,15,17,33,34 In our trial, the rates of local recurrence were not significantly different between patients who received chemoradiotherapy and those who did not receive chemoradiotherapy. Similar findings were reported in the EORTC trial.17 An analysis of 100,313 U.S. patients with pancreatic cancer in the National Cancer Database revealed that 9044 patients (9 percent) had undergone a pancreatectomy.8 Of these 9044 patients, only 39.9 percent had received adjuvant treatment: 6.5 percent had received radiotherapy, 5.1 percent chemotherapy, and 28.3 percent a combination of the two.8 The five-year survival rates were 23.3 percent after resection alone, 13.0 percent in the adjuvant-radiotherapy group, 17.4 percent in the adjuvant-chemotherapy group, and 17.0 percent in the combination-therapy group.8 Given such results, it is not surprising that there has been uncertainty regarding the use of adjuvant treatment for pancreatic cancer.
The survival curves in our trial began to separate in favor of adjuvant chemotherapy at 8 months after resection, but the curves showing the disadvantage of chemoradiotherapy did not begin to separate until 14 months. The simplest explanation for these observations is that chemoradiotherapy delayed the administration of chemotherapy (which in our trial resulted in a delay in both local and distant recurrences) and consequently reduced the potential benefit of chemotherapy that is derived from delivering it as soon as possible after resection. We conclude that standard care for patients with resectable pancreatic cancer should consist of curative surgery followed by adjuvant systemic chemotherapy.
Supported by Cancer Research United Kingdom and the Fonds de Recherche de la Société Nationale Française de Gastroentérologie; by a grant (9906195987) from the Consorzio Studi Universitari di Verona, Cariverona, and the Ministero Università e Ricerca Scientifica e Tecnologica, Rome; by the Associazione Italiana Ricerca Cancro, Milan, Italy; and by a European Community Grant (BMH4-CT98-3805).
Dr. Neoptolemos reports having received grant support from Solvay Pharmaceuticals and KS Biomedix.
We are indebted to Mrs. Jenny Almond and Mrs. Pat Baker, former ESPAC-1 trial coordinators, and to Professor Nick Lemoine, pathology advisor (Cancer Research United Kingdom, London).
Source Information
From the Department of Surgery, Liverpool University, Liverpool, United Kingdom (J.P.N., H.H.); the Cancer Research U.K. Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom (D.D.S., J.A.D., D.J.K.); the University of Heidelberg, Heidelberg, Germany (H.F., M.W.B.); the Surgical Department, University of Verona, Verona, Italy (C.B., M.F., P.P.); University Hospital of Surgery, Ulm, Germany (H.B.); Barcelona University Hospital, Barcelona, Spain (L.F.-C.); the Department of Surgery, Agia Olga Hospital, Athens, Greece (C.D.); the Service de Chirurgie Digestive et Générale, Hôpital Tenon, Paris (F.L.); the Department of Gastroenterology, Mav Hospital, Budapest, Hungary (A.P.); and the Department of Radiotherapy, Queen Elizabeth Hospital, Birmingham, United Kingdom (D.S.).
Appendix
The following persons participated in the ESPAC-1 Trial: Specialists — Austria: P. Steindorfer (Graz); Belgium: J.F. Gigot (Brussels); France (French Associations for Surgical Research): P. Segol (Caen); J. Chipponi (Clermont-Ferrand); J.M. Hay (Colombes); D. Cherqui, P.-L. Fagniez, B. Malassagne (Creteil); M.S. Sbai-Idrissy (Eaubonne); L. Gambiez, P. Quandalle, J.P. Triboulet (Lille); A. Gainant (Limoges); B. Derousseaux (Lomme); B. Sastre (Marseilles); S. Houry, H. Mosnier (Paris); M. Veyrieres (Pontoise); O. Bouche (Reims); G. Fourtanier (Toulouse); Germany: U. Kletha (Chemnitz); J. Schmidt (Heidelberg); J. Scheele (Jena); G. Weiand (Lahr); B. Gerdes (Marburg); W. Weber (Trier); Greece: J.K. Poulantzas (Athens); J. Androulakis (Patras); G. Blantzas, D. Botsios, E. Hatzitheoklitos, C.H. Sbarouris (Thessaloniki); Hungary: L. Flautner, T. Tihanyi (Budapest); P. Sapy (Debrecen); A. Olah (Gyor); P. Horvath-Õrs, D. Kelemen (Pecs); M. Wenczl (Szombathely); Italy: G. Marzoli (Bolzano); O. Pieramico (Meran); F. Meduri, S. Pedrazzoli (Padua); F. Dominioni (Varese); G. Butturini (Verona); Spain: C. Pera (Cordoba); Sweden: I. Ihse, Å. Andrén-Sandberg (Lund); Switzerland: S. Hunziker (Aarau); K. Buser (Bern); R. Stupp (Lausanne); J. Largiader (Lucerne); G. Pichert, R. Trüb (Zurich); United Kingdom: J. Buckels, I. Fernando (Birmingham); D. Alderson, S. Falk (Bristol); P. De Takats (Cambridge); R. Carter, D. Hochhauser, C. Imrie (Glasgow); T. Leese (Lancaster); A. Crellin, D. Sebag-Montefiore, M. Seymour (Leeds); D. Lloyd, F. Madden (Leicester); M. Hartley, S. Myint, J. Slavin, D. Smith, R. Sutton (Liverpool, Wirral); P. Price, B. Davidson (London); T. Podd (Newcastle); F. Daniel, A. Kingsnorth (Plymouth); C. Baughan, C. Johnson (Southampton); F. Adab (Stoke on Trent); D. Cunningham (Surrey); Independent Data and Safety Monitoring Committee — R.C.G. Russell (Middlesex Hospital, London), P. Clarke (Clatterbridge Center for Clinical Oncology, Wirral, United Kingdom), R.P. A'Hern (Royal Marsden Hospital, London); Trial Design — J.P. Neoptolemos, M.W. Büchler, H.G. Beger, C. Bassi, P. Pederzoli, D.J. Kerr, D. Spooner, J.A. Dunn; Recruitment — J.P. Neoptolemos, M.W. Büchler, H.G. Beger, C. Bassi, P. Pederzoli, D.J. Kerr, D. Spooner, J.A. Dunn, M. Falconi, C. Dervenis, F. Fernandez-Cruz, F. Lacaine, A. Pap, H. Friess; Statistical Analysis and Preparation of Reports — D.D. Stocken; Trial Coordinator — H. Hickey; Writing Committee — J.P. Neoptolemos, D.D. Stocken.
- References
References
1
Bramhall SR ,Allum WH ,Jones AG ,Allwood A ,Cummins C ,Neoptolemos JP . Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995;82:111-115
CrossRef | Web of Science | Medline2
Jemal A ,Murray T ,Samuels A ,Ghafoor A ,Ward E ,Thun MJ . Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26
CrossRef | Web of Science | Medline3
Fernandez E ,La Vecchia C ,Porta M ,Negri E ,Lucchini F ,Levi F . Trends in pancreatic cancer mortality in Europe, 1955-1989. Int J Cancer 1994;57:786-792
CrossRef | Web of Science | Medline4
Parkin DM ,Bray FI ,Devesa SS . Cancer burden in the year 2000: the global picture. Eur J Cancer 2001;37:Suppl 8:S4-S66
CrossRef | Web of Science | Medline5
Geer RJ ,Brennan MF . Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72
CrossRef | Web of Science | Medline6
Nitecki SS ,Sarr MG ,Colby TV ,van Heerden JA . Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg 1995;221:59-66
CrossRef | Web of Science | Medline7
Birkmeyer JD ,Warshaw AL ,Finlayson SR ,Grove MR ,Tosteson ANA . Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999;126:178-183
CrossRef | Web of Science | Medline8
Sener SF ,Fremgen A ,Menck HR ,Winchester DP . Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7
CrossRef | Web of Science | Medline9
Sohn TA ,Yeo CJ ,Cameron JL , et al. Resected adenocarcinoma of the pancreas -- 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579
CrossRef | Web of Science | Medline10
Griffin JF ,Smalley SR ,Jewell W , et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56-61
CrossRef | Web of Science | Medline11
Westerdhal J ,Andren-Sandberg A ,Ihse I . Recurrence of exocrine pancreatic cancer -- local or hepatic? Hepatogastroenterology 1993;40:384-387
Web of Science | Medline12
Sperti C ,Pasquali C ,Piccoli A ,Pedrazzoli S . Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195-200
CrossRef | Web of Science | Medline13
Neoptolemos JP ,Cunningham D ,Friess H , et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003;14:675-692
CrossRef | Web of Science | Medline14
Kalser MH ,Ellenberg SS . Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903[Erratum, Arch Surg 1986;121:1045.]
Web of Science | Medline15
Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-2010
CrossRef | Web of Science | Medline16
Lim JE ,Chien MW ,Earle CC . Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74-85
CrossRef | Web of Science | Medline17
Klinkenbijl JH ,Jeekel J ,Sahmoud T , et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-784
CrossRef | Web of Science | Medline18
Bakkevold KE ,Arnesjo B ,Dahl O ,Kambestad B . Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater -- results of a controlled, prospective, randomised multicenter study. Eur J Cancer 1993;29:698-703
CrossRef | Web of Science19
Takada T ,Amano H ,Yasuda H , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-1695
CrossRef | Web of Science | Medline20
Neoptolemos JP ,Dunn JA ,Stocken DD , et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-1585
CrossRef | Web of Science | Medline21
Neoptolemos JP ,Stocken DD ,Dunn JA , et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-768
CrossRef | Web of Science | Medline22
Jones L ,Russell C ,Mosca F , et al. Standard Kausch-Whipple pancreatoduodenectomy. Dig Surg 1999;16:297-304
CrossRef | Web of Science | Medline23
Aaronson NK ,Ahmedzai S ,Bergman B , et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376
CrossRef | Web of Science | Medline24
Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0. Bethesda, Md.: Division of Cancer Treatment & Diagnosis, National Institutes of Health, March 1998.
25
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science26
Peto R ,Pike MC ,Armitage P , et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39
CrossRef | Web of Science | Medline27
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22028
Early Breast Cancer Trialists' Collaborative Group. Introduction and methods sections reproduced from: Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford, England: Oxford University Press, 1990.
29
Qian W ,Parmar MKB ,Sambrook RJ ,Fayers PM ,Girling DJ ,Stephens RJ . Analysis of messy longitudinal data from a randomized clinical trial. Stat Med 2000;19:2657-2674
CrossRef | Web of Science | Medline30
Whittington R ,Bryer MP ,Haller DG ,Solin LJ ,Rosato EF . Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991;21:1137-1143
CrossRef | Web of Science | Medline31
Foo ML ,Gunderson LL ,Nagorney DM , et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys 1993;26:483-489
CrossRef | Web of Science | Medline32
Chakravarthy A ,Abrams RA ,Yeo CJ , et al. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys 2000;48:1089-1096
CrossRef | Web of Science | Medline33
Johnstone PA ,Sindelar WF . Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: correlations of a clinical trial. Int J Radiat Oncol Biol Phys 1993;27:831-834
CrossRef | Web of Science | Medline34
Willett CG ,Lewandrowski K ,Warshaw AL ,Efird J ,Compton CC . Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy. Ann Surg 1993;217:144-148
CrossRef | Web of Science | Medline
- Citing Articles (497)
Citing Articles
1
Robert M. Cannon, Ryan LeGrand, Ryaz B. Chagpar, Syed A. Ahmad, Rebecca McClaine, Hong Jin Kim, Christopher Rupp, Cliff S. Cho, Adam Brinkman, Sharon Weber, Emily R. Winslow, David A. Kooby, Carrie K. Chu, Charles A. Staley, Ian Glenn, William G. Hawkins, Alexander A. Parikh, Nipun B. Merchant, Kelly M. McMasters, Robert C.G. Martin, Glenda G. Callender, Charles R. Scoggins. (2012) Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPBno-no
CrossRef2
Alireza Aslani, Paul J. Roach, Ross C. Smith. (2012) Long-term changes in body composition after pancreaticoduodenectomy. ANZ Journal of Surgeryno-no
CrossRef3
M Sahraei, L D Roy, J M Curry, T L Teresa, S Nath, D Besmer, A Kidiyoor, R Dalia, S J Gendler, P Mukherjee. (2012) MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene
CrossRef4
Michele Reni, Gianpaolo Balzano, Giuseppe Aprile, Stefano Cereda, Paolo Passoni, Alessandro Zerbi, Maria Chiara Tronconi, Carlo Milandri, Piercarlo Saletti, Alessia Rognone, Clara Fugazza, Alessandro Magli, Nadia Di Muzio, Valerio Di Carlo, Eugenio Villa. (2012) Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial. Annals of Surgical Oncology
CrossRef5
Jordan M. Winter, Murray F. Brennan, Laura H. Tang, Michael I. D’Angelica, Ronald P. DeMatteo, Yuman Fong, David S. Klimstra, William R. Jarnagin, Peter J. Allen. (2012) Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades. Annals of Surgical Oncology 19:1, 169-175
CrossRef6
Romaine C. Nichols, Soon N. Huh, Karl L. Prado, Byong Y. Yi, Navesh K. Sharma, Meng W. Ho, Bradford S. Hoppe, Nancy P. Mendenhall, Zuofeng Li, William F. Regine. (2012) Protons Offer Reduced Normal-Tissue Exposure for Patients Receiving Postoperative Radiotherapy for Resected Pancreatic Head Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef7
David Páez, Melissa J. Labonte, Heinz-Josef Lenz. (2012) Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). Gastroenterology Clinics of North America
CrossRef8
Timothy M. Zagar, Rebekah R. White, Christopher G. Willett, Douglas S. Tyler, Paulie Papavassiliou, Katia T. Papalezova, Cynthia D. Guy, Gloria Broadwater, Robert W. Clough, Brian G. Czito. (2012) Resected Pancreatic Neuroendocrine Tumors: Patterns of Failure and Disease-Related Outcomes With or Without Radiotherapy. International Journal of Radiation Oncology*Biology*Physics
CrossRef9
Andrew D. Rhim, Emily T. Mirek, Nicole M. Aiello, Anirban Maitra, Jennifer M. Bailey, Florencia McAllister, Maximilian Reichert, Gregory L. Beatty, Anil K. Rustgi, Robert H. Vonderheide, Steven D. Leach, Ben Z. Stanger. (2012) EMT and Dissemination Precede Pancreatic Tumor Formation. Cell 148:1-2, 349-361
CrossRef10
Hiroshi Haeno, Mithat Gonen, Meghan B. Davis, Joseph M. Herman, Christine A. Iacobuzio-Donahue, Franziska Michor. (2012) Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies. Cell 148:1-2, 362-375
CrossRef11
Katia T. Papalezova, Douglas S. Tyler, Dan G. Blazer, Bryan M. Clary, Theodore N. Pappas, Rebekah R. White, Brian G. Czito, Christopher G. Willett, Herbert I. Hurwitz, Hope E. Uronis. (2012) Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?. Journal of Surgical Oncologyn/a-n/a
CrossRef12
Victor Molina, Laura Visa, Carles Conill, Salvador Navarro, Jose M. Escudero, Jose M. Auge, Xavier Filella, Miguel A. Lopez-Boado, Joana Ferrer, Laureano Fernandez-Cruz, Rafael Molina. (2011) CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumor Biology
CrossRef13
Hidefumi Aoyama. 2011. Assessing Radiation Therapy. , 255-268.
CrossRef14
Sohei Satoi, Hideyoshi Toyokawa, Hiroaki Yanagimoto, Tomohisa Yamamoto, Minoru Kamata, Chisato Ohe, Noriko Sakaida, Yoshiko Uemura, Hiroaki Kitade, Noboru Tanigawa, Kentaro Inoue, Yoichi Matsui, A-Hon Kwon. (2011) Neo-adjuvant Chemoradiation Therapy Using S-1 Followed by Surgical Resection in Patients with Pancreatic Cancer. Journal of Gastrointestinal Surgery
CrossRef15
Matthew M. Poppe, Venkat Narra, Ning J. Yue, Jinghao Zhou, Carl Nelson, Salma K. Jabbour. (2011) A Comparison of Helical Intensity-Modulated Radiotherapy, Intensity-Modulated Radiotherapy, and 3D-Conformal Radiation Therapy for Pancreatic Cancer. Medical Dosimetry 36:4, 351-357
CrossRef16
Terence C. Chua, Akshat Saxena. (2011) Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: A review of current results. Surgical Oncology 20:4, e161-e168
CrossRef17
Christoph M. Burdelski, Matthias Reeh, Dean Bogoevski, Florian Gebauer, Michael Tachezy, Yogesh K. Vashist, Guellue Cataldegirmen, Emre Yekebas, Jakob R. Izbicki, Maximilian Bockhorn. (2011) Multivisceral Resections in Pancreatic Cancer: Identification of Risk Factors. World Journal of Surgery 35:12, 2756-2763
CrossRef18
Jonathan A. Abelson, James D. Murphy, Ann Yuriko Minn, Melody Chung, George A. Fisher, James M. Ford, Pamela Kunz, Jeffrey A. Norton, Brendan C. Visser, George A. Poultsides, Albert C. Koong, Daniel T. Chang. (2011) Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics
CrossRef19
Andrew S. Barbas, Ryan S. Turley, Eugene P. Ceppa, Srinevas K. Reddy, Dan G. Blazer, Bryan M. Clary, Theodore N. Pappas, Douglas S. Tyler, Rebekah R. White, Sandhya A. Lagoo. (2011) Comparison of Outcomes and the Use of Multimodality Therapy in Young and Elderly People Undergoing Surgical Resection of Pancreatic Cancer. Journal of the American Geriatrics Societyn/a-n/a
CrossRef20
R. Jäger, A. de Vries. (2011) The role of radiochemotherapy in the multimodal treatment of pancreatic ductal adenocarcinoma: Standard procedure or individual decision?. memo - Magazine of European Medical Oncology 4:4, 260-264
CrossRef21
Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Akira Nakashima, Taijiro Sueda. (2011) Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection. Annals of Surgical Oncology
CrossRef22
Hanno Matthaei, Seung-Mo Hong, Skye C. Mayo, Marco dal Molin, Kelly Olino, Raghunandan Venkat, Michael Goggins, Joseph M. Herman, Barish H. Edil, Christopher L. Wolfgang, John L. Cameron, Richard D. Schulick, Anirban Maitra, Ralph H. Hruban. (2011) Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Annals of Surgical Oncology 18:12, 3493-3499
CrossRef23
Tomoo Kosuge, Yoshihiro Sakamoto, Hideki Ueno. (2011) Postoperative adjuvant therapy. Journal of Hepato-Biliary-Pancreatic Sciences 18:6, 792-796
CrossRef24
Skye C. Mayo, Marta M. Gilson, Joseph M. Herman, John L. Cameron, Hari Nathan, Barish H. Edil, Michael A. Choti, Richard D. Schulick, Christopher L. Wolfgang, Timothy M. Pawlik. (2011) Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant Therapy. Journal of the American College of Surgeons
CrossRef25
Chirlei Klein Büneker, Rui Yu, Laura Deedigan, Andrea Mohr, Ralf Michael Zwacka. (2011) IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells. Cancer Letters
CrossRef26
S.E. Combs, D. Habermehl, J. Werner, M.W. Büchler, J. Debus. (2011) Strategien für präoperatives Downsizing bei inoperablem Pankreaskarzinom. Der Chirurg 82:11, 981-988
CrossRef27
Yuji Nimura, Masato Nagino, Sonshin Takao, Tadahiro Takada, Koji Miyazaki, Yoshifumi Kawarada, Shuichi Miyagawa, Akihiro Yamaguchi, Shuichi Ishiyama, Yutaka Takeda, Kourou Sakoda, Taira Kinoshita, Kenzo Yasui, Hiroshi Shimada, Hiroyuki Katoh. (2011) Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Journal of Hepato-Biliary-Pancreatic Sciences
CrossRef28
Angelo Andriulli, Virginia Festa, Edoardo Botteri, Maria R. Valvano, Maurizio Koch, Claudio Bassi, Patrick Maisonneuve, Pierluigi Di Sebastiano. (2011) Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies. Annals of Surgical Oncology
CrossRef29
Mathias Worni, Igor Akushevich, Beat Gloor, John Scarborough, Junzo P. Chino, Danny O. Jacobs, Stephen M. Hahn, Bryan M. Clary, Ricardo Pietrobon, Anand Shah. (2011) Adjuvant Radiotherapy in the Treatment of Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas: an Analysis of the Surveillance, Epidemiology, and End Results Registry. Annals of Surgical Oncology
CrossRef30
Sheetal M Kircher, Seth B Krantz, Halla S Nimeiri, Mary F Mulcahy, Hidayatullah G Munshi, Al B Benson. (2011) Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Expert Review of Anticancer Therapy 11:10, 1555-1565
CrossRef31
Markus W. Büchler, Markus K. Diener, Jürgen Weitz. (2011) Scientific evaluation of modern clinical research: we need a new currency!. Langenbeck's Archives of Surgery 396:7, 937-939
CrossRef32
Yun Shin Chun, Harry S. Cooper, Steven J. Cohen, Andre Konski, Barbara Burtness, Crystal S. Denlinger, Igor Astsaturov, Michael J. Hall, John P. Hoffman. (2011) Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals of Surgical Oncology
CrossRef33
Yefei Rong, Xia Qin, Dayong Jin, Wenhui Lou, Lili Wu, Dansong Wang, Wenchuan Wu, Xiaolin Ni, Zhengfa Mao, Tiantao Kuang, Ying Qin Zang, Xinyu Qin. (2011) A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clinical and Experimental Medicine
CrossRef34
John P. Neoptolemos. (2011) Adjuvant treatment of pancreatic cancer. European Journal of Cancer 47, S378-S380
CrossRef35
Jörg-Christian Heinrich, Anne Tuukkanen, Michael Schroeder, Torsten Fahrig, Rudolf Fahrig. (2011) RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. Journal of Cancer Research and Clinical Oncology 137:9, 1349-1361
CrossRef36
Shishir K. Maithel, Ipek Coban, Peter J. Kneuertz, David A. Kooby, Bassel F. El-Rayes, John S. Kauh, Juan Sarmiento, Charles A. Staley, N. Volkan Adsay. (2011) Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection. Annals of Surgical Oncology 18:9, 2699-2705
CrossRef37
Edward J. Kim, Diane M. Simeone. (2011) Advances in pancreatic cancer. Current Opinion in Gastroenterology 27:5, 460-466
CrossRef38
Marjolein J.M. Morak, Peter M. van Koetsveld, Roland Kanaar, Leo J. Hofland, Casper H.J. van Eijck. (2011) Type I interferons as radiosensitisers for pancreatic cancer. European Journal of Cancer 47:13, 1938-1945
CrossRef39
C. Neuzillet, A. Sauvanet, P. Hammel. (2011) Prognostic factors for resectable pancreatic adenocarcinoma. Journal of Visceral Surgery 148:4, e232-e243
CrossRef40
C. Neuzillet, A. Sauvanet, P. Hammel. (2011) Facteurs pronostiques de l’adénocarcinome pancréatique résécable. Journal de Chirurgie Viscérale 148:4, 264-276
CrossRef41
Jacob P. VanHouten, Rebekah R. White, Gretchen Purcell Jackson. (2011) A Decision Model of Therapy for Potentially Resectable Pancreatic Cancer. Journal of Surgical Research
CrossRef42
Israel Vlodavsky, Phillip Beckhove, Immanuel Lerner, Claudio Pisano, Amichai Meirovitz, Neta Ilan, Michael Elkin. (2011) Significance of Heparanase in Cancer and Inflammation. Cancer Microenvironment
CrossRef43
Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Akira Nakashima, Hiroki Ohge, Taijiro Sueda. (2011) Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection. Journal of Surgical Oncology 104:2, 146-154
CrossRef44
Audrey Vincent, Joseph Herman, Rich Schulick, Ralph H Hruban, Michael Goggins. (2011) Pancreatic cancer. The Lancet 378:9791, 607-620
CrossRef45
J.- L. Van Laethem, C. Verslype, J. L. Iovanna, P. Michl, T. Conroy, C. Louvet, P. Hammel, E. Mitry, M. Ducreux, T. Maraculla, W. Uhl, G. Van Tienhoven, J. B. Bachet, R. Marechal, A. Hendlisz, M. Bali, P. Demetter, F. Ulrich, D. Aust, J. Luttges, M. Peeters, M. Mauer, A. Roth, J. P. Neoptolemos, M. Lutz. (2011) New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Annals of Oncology
CrossRef46
Carlos Gómez-Martín, Manuel Hidalgo, Josep Tabernero, Dolores Isla. (2011) SEOM clinical guidelines for the treatment of pancreatic cancer. Clinical and Translational Oncology 13:8, 528-535
CrossRef47
Parul J. Shukla. (2011) The Challenges of Improving Survival Following Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery 254:2, 385-386
CrossRef48
Kenoki Ohuchida, Kazuhiro Mizumoto, Tadashi Kayashima, Hayato Fujita, Taiki Moriyama, Takao Ohtsuka, Junji Ueda, Eishi Nagai, Makoto Hashizume, Masao Tanaka. (2011) MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer. Annals of Surgical Oncology 18:8, 2381-2387
CrossRef49
David P. Horowitz, Charles C. Hsu, Jingya Wang, Martin A. Makary, Jordan M. Winter, Ray Robinson, Richard D. Schulick, John L. Cameron, Timothy M. Pawlik, Joseph M. Herman. (2011) Adjuvant Chemoradiation Therapy After Pancreaticoduodenectomy in Elderly Patients With Pancreatic Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 80:5, 1391-1397
CrossRef50
Giovanni Vitale, Silvia Zappavigna, Monica Marra, Alessandra Dicitore, Stefania Meschini, Maria Condello, Giuseppe Arancia, Sara Castiglioni, Paola Maroni, Paola Bendinelli, Roberta Piccoletti, Peter M. van Koetsveld, Francesco Cavagnini, Alfredo Budillon, Alberto Abbruzzese, Leo J. Hofland, Michele Caraglia. (2011) The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnology Advances
CrossRef51
Giuliano Barugola, Stefano Partelli, Stefano Crippa, Paola Capelli, Mirko D'Onofrio, Paolo Pederzoli, Massimo Falconi. (2011) Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. The American Journal of Surgery
CrossRef52
Jan Franko, Dev R. Puri, Charles D. Goldman. (2011) Impact of Radiation Therapy Sequence on Survival Among Patients With Resected Pancreatic Head Ductal Carcinoma. Annals of Surgical Oncology
CrossRef53
Amer H. Zureikat, Jason A. Breaux, Jennifer L. Steel, Steven J. Hughes. (2011) Can Laparoscopic Pancreaticoduodenectomy Be Safely Implemented?. Journal of Gastrointestinal Surgery 15:7, 1151-1157
CrossRef54
M. A. Tempero, J. Berlin, M. Ducreux, D. Haller, P. Harper, D. Khayat, H.- J. Schmoll, A. Sobrero, E. Van Cutsem. (2011) Pancreatic cancer treatment and research: an international expert panel discussion. Annals of Oncology 22:7, 1500-1506
CrossRef55
Mechteld C. de Jong, Fuyu Li, John L. Cameron, Christopher L. Wolfgang, Barish H. Edil, Joseph M. Herman, Michael A. Choti, Frederick Eckhauser, Kenzo Hirose, Richard D. Schulick, Timothy M. Pawlik. (2011) Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. Journal of Surgical Oncology 103:7, 656-662
CrossRef56
Brian G Czito, Christopher G Willett. (2011) Potentially resectable pancreatic cancer in elderly patients: is surgery a reasonable choice?. Aging Health 7:3, 463-467
CrossRef57
Emily Castellanos, Jordan Berlin, Dana Backlund Cardin. (2011) Current Treatment Options for Pancreatic Carcinoma. Current Oncology Reports 13:3, 195-205
CrossRef58
Yong Chen, JiHui Hao, WeiDong Ma, Yong Tang, ChunTao Gao, XiShan Hao. (2011) Improvement in Treatment and Outcome of Pancreatic Ductal Adenocarcinoma in North China. Journal of Gastrointestinal Surgery 15:6, 1026-1034
CrossRef59
M. Barhoumi, F. Mornex, F. Bonnetain, P. Rougier, C. Mariette, O. Bouché, J.-F. Bosset, T. Aparicio, L. Mineur, A. Azzedine, P. Hammel, J. Butel, N. Stremsdoerfer, P. Maingon, L. Bedenne, B. Chauffert. (2011) Cancer du pancréas localement évolué non resécable : chimioradiothérapie d’induction suivie de chimiothérapie par gemcitabine contre chimiothérapie exclusive par gemcitabine : résultats définitifs de l’étude de phase III 2000–2001de la FFCD et de la SFRO. Cancer/Radiothérapie 15:3, 182-191
CrossRef60
Laura Bortesi, Anna Pesci, Giuseppe Bogina, Paola Castelli, Giuseppe Zamboni. (2011) Ductal Adenocarcinoma of the Pancreas. Surgical Pathology Clinics 4:2, 487-521
CrossRef61
Stefano Partelli, Stefano Crippa, Giuliano Barugola, Domenico Tamburrino, Paola Capelli, Mirko D’Onofrio, Paolo Pederzoli, Massimo Falconi. (2011) Splenic Artery Invasion in Pancreatic Adenocarcinoma of the Body and Tail: A Novel Prognostic Parameter for Patient Selection. Annals of Surgical Oncology
CrossRef62
Avo Artinyan, Daniel A. Anaya, Shaun McKenzie, Joshua D. I. Ellenhorn, Joseph Kim. (2011) Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 117:10, 2044-2049
CrossRef63
William F. Regine, Kathryn A. Winter, Ross Abrams, Howard Safran, John P. Hoffman, Andre Konski, Al B. Benson, John S. Macdonald, Tyvin A. Rich, Christopher G. Willett. (2011) Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial. Annals of Surgical Oncology 18:5, 1319-1326
CrossRef64
Suzanne Russo, Roger Ove, Carlo Contreras, Muhammad Wasif Saif. (2011) Adjuvant trials for pancreatic cancer: where are we going and what is needed?. Clinical Investigation 1:5, 651-667
CrossRef65
Baldassarre Stea, Lisa J. Hazard, Victor J. Gonzalez, Russell Hamilton. (2011) The role of radiation therapy in the control of locoregional and metastatic cancer. Journal of Surgical Oncology 103:6, 627-638
CrossRef66
Isabelle Trouilloud, Olivier Dubreuil, Tarek Boussaha, Céline Lepère, Bruno Landi, Aziz Zaanan, Jean-Baptiste Bachet, Julien Taieb. (2011) Medical treatment of pancreatic cancer: New hopes after 10years of gemcitabine. Clinics and Research in Hepatology and Gastroenterology 35:5, 364-374
CrossRef67
R A Smith, J Tang, C Tudur-Smith, J P Neoptolemos, P Ghaneh. (2011) Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. British Journal of Cancer 104:9, 1440-1451
CrossRef68
R. Le Scodan, F. Mornex, C. Partensky, C. Mercier, P.-J. Valette, M. Ychou, F. Bibeau, J.-Y. Scoazec. (2011) Chimioradiothérapie préopératoire des adénocarcinomes du pancréas : évaluation anatomopathologique de l’efficacité thérapeutique. Cancer/Radiothérapie 15:2, 97-105
CrossRef69
Philip Q. Bao, Ramesh K. Ramanathan, Alyssa Krasinkas, Nathan Bahary, Barry C. Lembersky, David L. Bartlett, Steven J. Hughes, Kenneth K. Lee, A. James Moser, Herbert J. Zeh. (2011) Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology 18:4, 1122-1129
CrossRef70
Giuseppe Malleo, Giovanni Marchegiani, Roberto Salvia, Giovanni Butturini, Paolo Pederzoli, Claudio Bassi. (2011) Pancreaticoduodenectomy for pancreatic cancer: The Verona experience. Surgery Today 41:4, 463-470
CrossRef71
Qiang Xu, Tai-Ping Zhang, Yu-Pei Zhao. (2011) Advances in early diagnosis and therapy of pancreatic cancer. Hepatobiliary & Pancreatic Diseases International 10:2, 128-135
CrossRef72
Thilo Welsch, Luca Degrate, Stefanie Zschäbitz, Stefan Hofer, Jens Werner, Jan Schmidt. (2011) The need for extended intensive care after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Langenbeck's Archives of Surgery 396:3, 353-362
CrossRef73
Autumn J McRee, Stacy Cowherd, Andrew Z Wang, Richard M Goldberg. (2011) Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncology 7:3, 409-426
CrossRef74
Jong-Kook Park, Jon C. Henry, Jinmai Jiang, Christine Esau, Yuriy Gusev, Megan R. Lerner, Russell G. Postier, Daniel J. Brackett, Thomas D. Schmittgen. (2011) miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochemical and Biophysical Research Communications 406:4, 518-523
CrossRef75
Weijing Sun, James M. Metz, Maryann Gallagher, Peter J. O’Dwyer, Bruce Giantonio, Richard Whittington, Daniel G. Haller. (2011) Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. Cancer Chemotherapy and Pharmacology 67:3, 621-627
CrossRef76
Ren Nishio, Hiroyuki Tsuchiya, Toshihiro Yasui, Shizuka Matsuura, Keita Kanki, Akihiro Kurimasa, Ichiro Hisatome, Goshi Shiota. (2011) Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Science 102:3, 622-629
CrossRef77
Nigel Balfour Jamieson, Alan K. Foulis, Karin A. Oien, Euan J. Dickson, Clem W. Imrie, Ross Carter, Colin J. McKay. (2011) Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery 15:3, 512-524
CrossRef78
Jin-Young Jang, Dae Wook Hwang, Min A. Kim, Mee-Joo Kang, Chang Sup Lim, Seung Eun Lee, Sun-Whe Kim. (2011) Analysis of Prognostic Factors and a Proposed New Classification for Invasive Papillary Mucinous Neoplasms. Annals of Surgical Oncology 18:3, 644-650
CrossRef79
Hanno Matthaei, Seung-Mo Hong, Skye C. Mayo, Marco Molin, Kelly Olino, Raghunandan Venkat, Michael Goggins, Joseph M. Herman, Barish H. Edil, Christopher L. Wolfgang, John L. Cameron, Richard D. Schulick, Anirban Maitra, Ralph H. Hruban. (2011) Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Indian Journal of Surgical Oncology 2:1, 9-15
CrossRef80
Synne Wedén, Marianne Klemp, Ivar P. Gladhaug, Mona Møller, Jon Amund Eriksen, Gustav Gaudernack, Trond Buanes. (2011) Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. International Journal of Cancer 128:5, 1120-1128
CrossRef81
Robert N Whistance, Jane M Blazeby. (2011) Systematic review: quality of life after treatment for upper gastrointestinal cancer. Current Opinion in Supportive and Palliative Care 5:1, 37-46
CrossRef82
V. J. Picozzi, R. A. Abrams, P. A. Decker, W. Traverso, E. M. O'Reilly, E. Greeno, R. C. Martin, L. S. Wilfong, M. L. Rothenberg, M. C. Posner, P. W. T. Pisters, . (2011) Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Annals of Oncology 22:2, 348-354
CrossRef83
Jean-Claude M. Rwigema, Simul D. Parikh, Dwight E. Heron, Michael Howell, Herbert Zeh, A. James Moser, Nathan Bahary, Annette Quinn, Steven A. Burton. (2011) Stereotactic Body Radiotherapy in the Treatment of Advanced Adenocarcinoma of the Pancreas. American Journal of Clinical Oncology 34:1, 63-69
CrossRef84
Lutz Eric, Charles J. Yeo, Keith D. Lillemoe, Barbara Biedrzycki, Barry Kobrin, Joseph Herman, Elizabeth Sugar, Steven Piantadosi, John L. Cameron, Sara Solt, Beth Onners, Irena Tartakovsky, Miri Choi, Rajni Sharma, Peter B. Illei, Hruban Ralph H., Ross A. Abrams, Dung Le, Jaffee Elizabeth, Dan Laheru. (2011) A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma. Annals of Surgery 253:2, 328-335
CrossRef85
, Matthew H. G. Katz, Nipun B. Merchant, Steven Brower, Megan Branda, Mitchell C. Posner, L. William Traverso, Ross A. Abrams, Vincent J. Picozzi, Peter W. T. Pisters. (2011) Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial. Annals of Surgical Oncology 18:2, 337-344
CrossRef86
Takaharu Yasui, Kenoki Ohuchida, Ming Zhao, Manabu Onimaru, Takuya Egami, Hayato Fujita, Takao Ohtsuka, Kazuhiro Mizumoto, Masao Tanaka. (2011) Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway. Cancer Science 102:2, 484-491
CrossRef87
Eileen M O’Reilly. (2011) Adjuvant therapy for pancreas adenocarcinoma: where are we going?. Expert Review of Anticancer Therapy 11:2, 173-177
CrossRef88
Ross A. Abrams, Kathryn A. Winter, William F. Regine, Howard Safran, John P. Hoffman, Robert Lustig, Andre A. Konski, Al B. Benson, John S. Macdonald, Tyvin A. Rich. (2011) Failure to Adhere to Protocol Specified Radiation Therapy Guidelines was Associated with Decreased Survival in RTOG 9704—A Phase III Trial of Adjuvant Chemotherapy and Chemoradiotherapy for Patients with Resected Adenocarcinoma of the Pancreas. International Journal of Radiation OncologyBiologyPhysics
CrossRef89
Adam Lister, Taoufik Nedjadi, Neil R Kitteringham, Fiona Campbell, Eithne Costello, Bryony Lloyd, Ian M Copple, Samantha Williams, Andrew Owen, John P Neoptolemos, Chris E Goldring, B Kevin Park. (2011) Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer 10:1, 37
CrossRef90
Stefan Heinrich, Bernhard Pestalozzi, Mickael Lesurtel, Frederik Berrevoet, Stéphanie Laurent, Jean-Robert Delpero, Jean-Luc Raoul, Phillippe Bachellier, Patrick Dufour, Markus Moehler, Achim Weber, Hauke Lang, Xavier Rogiers, Pierre-Alain Clavien. (2011) Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 11:1, 346
CrossRef91
Louise Barbier, Olivier Turrini, Emilie Grégoire, Frédéric Viret, Yves-Patrice Le Treut, Jean-Robert Delpero. (2011) Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. HPB 13:1, 64-69
CrossRef92
Shigeo Koido, Sadamu Homma, Akitaka Takahara, Yoshihisa Namiki, Shintaro Tsukinaga, Jimi Mitobe, Shunichi Odahara, Toyokazu Yukawa, Hiroshi Matsudaira, Keisuke Nagatsuma, Kan Uchiyama, Kenichi Satoh, Masaki Ito, Hideo Komita, Hiroshi Arakawa, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri. (2011) Current Immunotherapeutic Approaches in Pancreatic Cancer. Clinical and Developmental Immunology 2011, 1-15
CrossRef93
Skye C. Mayo, Hari Nathan, John L. Cameron, Kelly Olino, Barish H. Edil, Joseph M. Herman, Kenzo Hirose, Richard D. Schulick, Michael A. Choti, Christopher L. Wolfgang, Timothy M. Pawlik. (2011) Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancern/a-n/a
CrossRef94
Shunji Nagai, Tsutomu Fujii, Yasuhiro Kodera, Mitsuro Kanda, Tevfik T. Sahin, Akiyuki Kanzaki, Suguru Yamada, Hiroyuki Sugimoto, Shuji Nomoto, Shin Takeda, Satoshi Morita, Akimasa Nakao. (2011) Prognostic Implications of Intraoperative Radiotherapy for Unresectable Pancreatic Cancer. Pancreatology 11:1, 68-75
CrossRef95
Carmen Timke, Hubertus Winnenthal, Felix Klug, Falk FF Roeder, Andreas Bonertz, Christoph Reissfelder, Nathalie Rochet, Moritz Koch, Christine Tjaden, Markus W Buechler, Juergen Debus, Jens Werner, Philipp Beckhove, Jürgen Weitz, Peter E Huber. (2011) Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer. BMC Cancer 11:1, 134
CrossRef96
Nuh N Rahbari, Thomas Schmidt, Christine S Falk, Ulf Hinz, Magdalene Herber, Ulrich Bork, Markus W Büchler, Jürgen Weitz, Moritz Koch. (2011) Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 11:1, 286
CrossRef97
Manfred P. Lutz, Georg Kien. (2011) Adjuvante Therapie und Nachsorge bei zystischem Malignom. Viszeralmedizin 27:3, 1-1
CrossRef98
Stefano Crippa, Domenico Tamburrino, Stefano Partelli, Roberto Salvia, Silvia Germenia, Claudio Bassi, Paolo Pederzoli, Massimo Falconi. (2011) Total pancreatectomy: Indications, different timing, and perioperative and long-term outcomes. Surgery 149:1, 79-86
CrossRef99
Eun Ran Kim, Sun Youn Bae, Kwang Hyuk Lee, Kyu Taek Lee, Hee Jung Son, Jong Chul Rhee, Jong Kyun Lee. (2011) Is Health Screening Beneficial for Early Detection and Prognostic Improvement in Pancreatic Cancer?. Gut and Liver 5:2, 194
CrossRef100
Christopher M. Halloran, Trevor F. Cox, Seema Chauhan, Michael G.T. Raraty, Robert Sutton, John P. Neoptolemos, Paula Ghaneh. (2011) Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study. Pancreatology 11:6, 535-545
CrossRef101
Paul H. Sugarbaker, O. Anthony Stuart, Lana Bijelic. (2011) Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data. International Journal of Surgical Oncology 2011, 1-7
CrossRef102
Kyoung Won Yoon, Jin Seok Heo, Dong Wook Choi, Seoung Ho Choi. (2011) Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma. Journal of the Korean Surgical Society 81:6, 394
CrossRef103
John H Heinzerling, Ross Bland, John C Mansour, Roderich E Schwarz, Ezequiel Ramirez, Chuxiong Ding, Ramzi Abdulrahman, Thomas P Boike, Timothy Solberg, Robert D Timmerman, Jeffrey J Meyer. (2011) Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. Radiation Oncology 6:1, 146
CrossRef104
Verena Ellerkamp, Steven W. Warmann, Peter Vorwerk, Ivo Leuschner, Joerg Fuchs. (2011) Exocrine pancreatic tumors in childhood in Germany. Pediatric Blood & Cancern/a-n/a
CrossRef105
Jan Sperveslage, Sunna Frank, Carola Heneweer, Jan Egberts, Bodo Schniewind, Malte Buchholz, Frank Bergmann, Nathalia Giese, Johanna Munding, Stephan Hahn, Holger Kalthoff, Günter Klöppel, Bence Sipos. (2011) Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. International Journal of Cancern/a-n/a
CrossRef106
Tae Hyun Kim, Sung-Sik Han, Sang-Jae Park, Woo Jin Lee, Sang Myung Woo, Tae Yoo, Sung Ho Moon, Seong Hoon Kim, Eun Kyung Hong, Dae Yong Kim. (2010) CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer. International Journal of Radiation OncologyBiologyPhysics
CrossRef107
Juan Fabregat, Juli Busquets, Núria Peláez, Rosa Jorba, Francisco García-Borobia, Cristina Masuet, Carlos Valls, Sandra Ruiz-Osuna, Teresa Serrano, Maica Galán, María Cambray, Berta Laquente, Emilio Ramos, Antoni Rafecas. (2010) Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (parte 2). Seguimiento a largo plazo tras 204 casos. Cirugía Española 88:6, 374-382
CrossRef108
Xi-Yan Wang, Hai-Jun Li, Hao Wen, Dong Yan, Shu-Yong Peng. (2010) Influence of the adjuvant therapy on the survival of patients with stage II pancreatic carcinoma. Frontiers of Medicine in China 4:4, 430-435
CrossRef109
Brian G. Czito, Christopher G. Willett. (2010) Adjuvant Radiation Therapy for Distal Pancreatic Cancer: Is There a Role?. Annals of Surgical Oncology 17:12, 3082-3084
CrossRef110
Frederik Fakelman, Klaus Felix, Markus W. Büchler, Jens Werner. (2010) New pre-analytical approach for the deep proteome analysis of sera from pancreatitis and pancreas cancer patients. Archives Of Physiology And Biochemistry 116:4-5, 208-217
CrossRef111
, Mehdi Ouaissi, Catherine Hubert, Robert Verhelst, Parla Astarci, Christine Sempoux, Anne Jouret-Mourin, Anderson Loundou, Jean-François Gigot. (2010) Vascular Reconstruction During Pancreatoduodenectomy for Ductal Adenocarcinoma of the Pancreas Improves Resectability but does not Achieve Cure. World Journal of Surgery 34:11, 2648-2661
CrossRef112
Timothy N. Showalter, Kathryn A. Winter, Adam C. Berger, William F. Regine, Ross A. Abrams, Howard Safran, John P. Hoffman, Al B. Benson, John S. MacDonald, Christopher G. Willett. (2010) The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Node Ratio on Survival after Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer: A Secondary Analysis of RTOG 9704. International Journal of Radiation OncologyBiologyPhysics
CrossRef113
P. Hammel, F. Huguet, M. Zappa, S. Dokmak, A. Sauvanet, A. Sa Cunha, J. -R. Delpero, F. Lacaine. (2010) Point de vue sur les traitements adjuvant et néoadjuvant du cancer du pancréas en 2010. Oncologie 12:10, 629-635
CrossRef114
Thilo Hackert, Markus W. Büchler. (2010) Vascular resections in pancreatic cancer. Updates in Surgery 62:2, 73-74
CrossRef115
O. Turrini, M. Ychou, L. Moureau-Zabotto, P. Rouanet, M. Giovannini, V. Moutardier, D. Azria, J.-R. Delpero, F. Viret. (2010) Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. European Journal of Surgical Oncology (EJSO) 36:10, 987-992
CrossRef116
Mukund S. Didolkar, Cardella W. Coleman, Mark J. Brenner, Kyo U. Chu, Nicole Olexa, Elizabeth Stanwyck, Airong Yu, Nagaraj Neerchal, Stuart Rabinowitz. (2010) Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients. Journal of Gastrointestinal Surgery 14:10, 1547-1559
CrossRef117
Richard E. Royal, Catherine Levy, Keli Turner, Aarti Mathur, Marybeth Hughes, Udai S. Kammula, Richard M. Sherry, Suzanne L. Topalian, James C. Yang, Israel Lowy, Steven A. Rosenberg. (2010) Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma. Journal of Immunotherapy 33:8, 828-833
CrossRef118
Francisco J. Padillo, Juan F. Ruiz-Rabelo, Adolfo Cruz, María D. Perea, Inmaculada Tasset, Pedro Montilla, Isaac Túnez, Jordi Muntané. (2010) Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. Journal of Pineal Research 49:3, 264-270
CrossRef119
David J Sher. (2010) Cost–effectiveness studies in radiation therapy. Expert Review of Pharmacoeconomics & Outcomes Research 10:5, 567-582
CrossRef120
Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura, Yasuo Hayashidani, Takeshi Sudo, Yasushi Hashimoto, Akira Nakashima, Ryutaro Sakabe, Norifumi Shigemoto, Yasushi Kato, Hiroki Ohge, Taijiro Sueda. (2010) Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer. Annals of Surgical Oncology 17:9, 2321-2329
CrossRef121
Eva Jöst, Wynand P. Roos, Bernd Kaina, Heinz Schmidberger. (2010) Response of pancreatic cancer cells treated with interferon-α or β and co-exposed to ionising radiation. International Journal of Radiation Biology 86:9, 732-741
CrossRef122
R. Gillmore, V. Laurence, S. Raouf, J. Tobias, G. Blackman, T. Meyer, K. Goodchild, C. Collis, J. Bridgewater. (2010) Chemoradiotherapy with or without Induction Chemotherapy for Locally Advanced Pancreatic Cancer: a UK Multi-institutional Experience. Clinical Oncology 22:7, 564-569
CrossRef123
Nabil Wasif, Clifford Y. Ko, James Farrell, Zev Wainberg, Oscar J. Hines, Howard Reber, James S. Tomlinson. (2010) Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging?. Annals of Surgical Oncology 17:9, 2312-2320
CrossRef124
Jean-Claude M. Rwigema, Dwight E. Heron, Simul D. Parikh, Herbert J. Zeh, James A. Moser, Nathan Bahary, Karlotta Ashby, Steven A. Burton. (2010) Adjuvant Stereotactic Body Radiotherapy for Resected Pancreatic Adenocarcinoma with Close or Positive Margins. Journal of Gastrointestinal Cancer
CrossRef125
Charbel Sandroussi, Chantelle Brace, Erin D. Kennedy, Nancy N. Baxter, Steven Gallinger, Alice C. Wei. (2010) Sociodemographics and Comorbidities Influence Decisions to Undergo Pancreatic Resection for Neoplastic Lesions. Journal of Gastrointestinal Surgery 14:9, 1401-1408
CrossRef126
H Kiefel, S Bondong, N Erbe-Hoffmann, J Hazin, S Riedle, J Wolf, M Pfeifer, A Arlt, H Schäfer, S Sebens Müerköster, P Altevogt. (2010) L1CAM–integrin interaction induces constitutive NF-κB activation in pancreatic adenocarcinoma cells by enhancing IL-1β expression. Oncogene 29:34, 4766-4778
CrossRef127
Virginia Sun. (2010) Update on Pancreatic Cancer Treatment. The Nurse Practitioner 35:8, 16-22
CrossRef128
Mee Joo Kang, Jin-Young Jang, Seung Eun Lee, Chang-Sup Lim, Kuhn Uk Lee, Sun-Whe Kim. (2010) Comparison of the long-term outcomes of uncinate process cancer and non-uncinate process pancreas head cancer: poor prognosis accompanied by early locoregional recurrence. Langenbeck's Archives of Surgery 395:6, 697-706
CrossRef129
Kazuhiro Kitajima, Koji Murakami, Erena Yamasaki, Yasushi Kaji, Mitsugi Shimoda, Keiichi Kubota, Narufumi Suganuma, Kazuro Sugimura. (2010) Performance of Integrated FDG-PET/Contrast-enhanced CT in the Diagnosis of Recurrent Pancreatic Cancer: Comparison with Integrated FDG-PET/Non-contrast-enhanced CT and Enhanced CT. Molecular Imaging and Biology 12:4, 452-459
CrossRef130
Matthew H. G. Katz, Gauri R. Varadhachary, Jason B. Fleming, Robert A. Wolff, Jeffrey E. Lee, Peter W. T. Pisters, Jean-Nicolas Vauthey, Eddie K. Abdalla, Charlotte C. Sun, Huamin Wang, Christopher H. Crane, Jeffrey H. Lee, Eric P. Tamm, James L. Abbruzzese, Douglas B. Evans. (2010) Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation. Annals of Surgical Oncology 17:7, 1794-1801
CrossRef131
Tadashi Uwagawa, Takeyuki Misawa, Tomonori Iida, Taro Sakamoto, Takeshi Gocho, Shigeki Wakiyama, Shoichi Hirohara, Katsuhiko Yanaga. (2010) Proton-Pump Inhibitor as Palliative Care for Chemotherapy-Induced Gastroesophageal Reflux Disease in Pancreatic Cancer Patients. Journal of Palliative Medicine 13:7, 815-818
CrossRef132
David T. Miyamoto, Harvey J. Mamon, David P. Ryan, Christopher G. Willett, Marek Ancukiewicz, Wendy K. Kobayashi, Lawrence Blaszkowsky, Carlos Fernandez-del Castillo, Theodore S. Hong. (2010) Outcomes and Tolerability of Chemoradiation Therapy for Pancreatic Cancer Patients Aged 75 Years or Older. International Journal of Radiation Oncology*Biology*Physics 77:4, 1171-1177
CrossRef133
Theodore P. McDade, Joshua S. Hill, Jessica P. Simons, Bilal Piperdi, Sing Chau Ng, Zheng Zhou, Sidney P. Kadish, Thomas J. Fitzgerald, Jennifer F. Tseng. (2010) A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma. Cancer 116:13, 3257-3266
CrossRef134
Skye C. Mayo, Donald F. Austin, Brett C. Sheppard, Motomi Mori, Donald K. Shipley, Kevin G. Billingsley. (2010) Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 116:12, 2932-2940
CrossRef135
J. Yamamoto, A. Saiura, R. Koga, M. Seki, M. Katori, Y. Kato, Y. Sakamoto, N. Kokudo, T. Yamaguchi. (2010) Improved Survival of Left-sided Pancreas Cancer after Surgery. Japanese Journal of Clinical Oncology 40:6, 530-536
CrossRef136
H. Oettle, U. Pelzer, J. Stieler, H. Riess. (2010) Adjuvante und palliative Therapie des Pankreaskarzinoms. Der Onkologe 16:6, 595-603
CrossRef137
Jing Li, M. Guillaume Wientjes, Jessie L.-S. Au. (2010) Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery. The AAPS Journal 12:2, 223-232
CrossRef138
Song-bing He, De-chun Li. (2010) Mutated genes in pancreatic cancer. Chinese Journal of Cancer Research 22:2, 93-98
CrossRef139
Keisuke Mitsuoka, Yukio Kato, Sosuke Miyoshi, Yoshihiro Murakami, Mariko Hiraiwa, Yoshiyuki Kubo, Shintaro Nishimura, Akira Tsuji. (2010) Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells. European Journal of Pharmaceutical Sciences 40:3, 202-208
CrossRef140
Salvador Navarro, Eva Vaquero, Joan Maurel, Josep Antoni Bombí, Carmen De Juan, Jaime Feliu, Laureano Fernández Cruz, Àngels Ginés, Enrique Girela, Ricardo Rodríguez, Luis Sabater. (2010) Recomendaciones para el diagnóstico, estadificación y tratamiento del cáncer de páncreas (parte ii). Medicina Clínica 134:15, 692-702
CrossRef141
M. Soufi, M. Bensaid, S. Benamr, R. Messrouri, J. Mdaghri, H. Essadel, M.K. Lahlou, E.H. Mohammadine, A. Taghy, A. Settaf, B. Chad. (2010) Quelle est la place de la chirurgie dans l’adénocarcinome pancréatique localement évolué ?. Journal Africain du Cancer / African Journal of Cancer 2:2, 98-103
CrossRef142
Bengt Glimelius. (2010) Any progress in pancreatic cancer? Well, but progress for Acta Oncologica. Acta Oncologica 49:4, 404-406
CrossRef143
Vlad V. Simianu, Nicholas J. Zyromski, Attila Nakeeb, Keith D. Lillemoe. (2010) Pancreatic cancer: Progress made. Acta Oncologica 49:4, 407-417
CrossRef144
Sarah C. Thomasset, Dileep N. Lobo. (2010) Pancreatic cancer. Surgery (Oxford) 28:5, 198-204
CrossRef145
S. Cascinu, M. Falconi, V. Valentini, S. Jelic, . (2010) Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v55-v58
CrossRef146
Alessio G. Morganti, Vincenzo Picardi, Edy Ippolito, Mariangela Massaccesi, Gabriella Macchia, Francesco Deodato, Gian Carlo Mattiucci, Luciana Caravatta, Liberato Di Lullo, Gianfranco Giglio, Rosa Tambaro, Samantha Mignogna, Paola Caprino, Marcello Ingrosso, Luigi Sofo, Numa Cellini, Vincenzo Valentini. (2010) Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. Acta Oncologica 49:4, 418-422
CrossRef147
Hidalgo, Manuel, . (2010) Pancreatic Cancer. New England Journal of Medicine 362:17, 1605-1617
Full Text148
Dana C. Backlund, Jordan D. Berlin, Alexander A. Parikh. (2010) Update on Adjuvant Trials for Pancreatic Cancer. Surgical Oncology Clinics of North America 19:2, 391-409
CrossRef149
J. Gaedcke, B. Gunawan, M. Grade, R. Szöke, T. Liersch, H. Becker, B. M. Ghadimi. (2010) The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbeck's Archives of Surgery 395:4, 451-458
CrossRef150
Andreas Hilbig, Helmut Oettle. (2010) Adjuvant therapy of pancreatic cancer. Expert Review of Anticancer Therapy 10:4, 485-491
CrossRef151
Liesbet Vervoort, Ingrid Burvenich, Steven Staelens, Caroline Dumolyn, Els Waegemans, Magali Van Steenkiste, Sarah K. Baird, Andrew M. Scott, Filip De Vos. (2010) Preclinical Evaluation of Monoclonal Antibody 14C5 for Targeting Pancreatic Cancer. Cancer Biotherapy & Radiopharmaceuticals 25:2, 193-205
CrossRef152
M. Schneider, J. Werner, J. Weitz, M.W. Büchler. (2010) Organisation der klinischen Forschung. Der Chirurg 81:4, 341-346
CrossRef153
Christopher H. Crane, Gauri R. Varadhachary, Robert A. Wolff, Jason B. Fleming. (2010) Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy. Annals of Surgical Oncology 17:4, 950-952
CrossRef154
Thilo Hackert, Markus W. Büchler, Jens Werner. (2010) Surgical Treatmant of Pancreatic Cancer. Polish Journal of Surgery 82:4, 251-257
CrossRef155
Jessica P. Simons, Sing Chau Ng, Theodore P. McDade, Zheng Zhou, Craig C. Earle, Jennifer F. Tseng. (2010) Progress for resectable cancer?. Cancer 116:7, 1681-1690
CrossRef156
Shayna L Showalter, Ziqiu Wang, Christina L Costantino, Agnieszka K Witkiewicz, Charles J Yeo, Jonathan R Brody, Brian I Carr. (2010) Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway. Journal of Gastroenterology and Hepatology 25:4, 738-744
CrossRef157
Charles C. Hsu, Joseph M. Herman, Michele M. Corsini, Jordan M. Winter, Matthew D. Callister, Michael G. Haddock, John L. Cameron, Timothy M. Pawlik, Richard D. Schulick, Christopher L. Wolfgang, Daniel A. Laheru, Michael B. Farnell, Michael J. Swartz, Leonard L. Gunderson, Robert C. Miller. (2010) Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study. Annals of Surgical Oncology 17:4, 981-990
CrossRef158
May Piperdi, Theodore P. McDade, Joon K. Shim, Bilal Piperdi, Sidney P. Kadish, Mary E. Sullivan, Giles F. Whalen, Jennifer F. Tseng. (2010) A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database. HPB 12:3, 204-210
CrossRef159
Daniel Renouf, Malcolm Moore. (2010) Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy 10:4, 529-540
CrossRef160
Daniel E. Abbott, Marshall S. Baker, Mark S. Talamonti. (2010) Neoadjuvant therapy for pancreatic cancer: A current review. Journal of Surgical Oncology 101:4, 315-320
CrossRef161
Anastasios Stathis, Malcolm J. Moore. (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology 7:3, 163-172
CrossRef162
Melissa Oliveira-Cunha, Richard J. Byers, Ajith K. Siriwardena. (2010) Poly(Adenylic Acid) Complementary DNA Real-Time Polymerase Chain Reaction in Pancreatic Ductal Juice in Patients Undergoing Pancreaticoduodenectomy. Pancreas 39:2, 171-174
CrossRef163
Michael J. Swartz, Charles C. Hsu, Timothy M. Pawlik, Jordan Winter, Ralph H. Hruban, Mehmet Guler, Richard D. Schulick, John L. Cameron, Daniel A. Laheru, Christopher L. Wolfgang, Joseph M. Herman. (2010) Adjuvant Chemoradiotherapy After Pancreatic Resection for Invasive Carcinoma Associated With Intraductal Papillary Mucinous Neoplasm of the Pancreas. International Journal of Radiation Oncology*Biology*Physics 76:3, 839-844
CrossRef164
Marjolein J. M. Morak, Chulja J. Pek, Erwin J. O. Kompanje, Wim C. J. Hop, Geert Kazemier, Casper H. J. van Eijck. (2010) Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer. Cancer 116:4, 830-836
CrossRef165
Rebecca J. McClaine, Andrew M. Lowy, Jeffrey J. Sussman, Nathan Schmulewitz, David L. Grisell, Syed A. Ahmad. (2010) Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB 12:1, 73-79
CrossRef166
Anand P. Shah, Jonathan B. Strauss, Ross A. Abrams. (2010) Review and Commentary on the Role of Radiation Therapy in the Adjuvant Management of Pancreatic Cancer. American Journal of Clinical Oncology 33:1, 101-106
CrossRef167
Andrew J. Russ, Sharon M. Weber, Robert J. Rettammel, David M. Mahvi, Layton F. Rikkers, Clifford S. Cho. (2010) Impact of Selection Bias on the Utilization of Adjuvant Therapy for Pancreas Adenocarcinoma. Annals of Surgical Oncology 17:2, 371-376
CrossRef168
E. Hudson, C. Hurt, D. Mort, A.E. Brewster, N. Iqbal, G. Joseph, T.D.L. Crosby, S. Mukherjee. (2010) Induction Chemotherapy Followed by Chemoradiation in Locally Advanced Pancreatic Cancer: an Effective and Well-tolerated Treatment. Clinical Oncology 22:1, 27-35
CrossRef169
R. Girelli, I. Frigerio, R. Salvia, E. Barbi, P. Tinazzi Martini, C. Bassi. (2010) Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. British Journal of Surgery 97:2, 220-225
CrossRef170
Udo Rudloff, Ajay V. Maker, Murray F. Brennan, Peter J. Allen. (2010) Randomized Clinical Trials in Pancreatic Adenocarcinoma. Surgical Oncology Clinics of North America 19:1, 115-150
CrossRef171
Jens Werner, Thilo Hackert, Markus W. Büchler. (2010) Surgical Treatmant of Pancreatic Cancer. Polish Journal of Surgery 82:4, 251
CrossRef172
Boris Hristov, Sushanth Reddy, Steven H. Lin, John L. Cameron, Timothy M. Pawlik, Ralph H. Hruban, Michael J. Swartz, Barish H. Edil, Clinton Kemp, Christopher L. Wolfgang, Joseph M. Herman. (2010) Outcomes of Adjuvant Chemoradiation After Pancreaticoduodenectomy With Mesenterico-Portal Vein Resection for Adenocarcinoma of the Pancreas. International Journal of Radiation Oncology*Biology*Physics 76:1, 176-180
CrossRef173
Alessio G. Morganti, Mariangela Massaccesi, Giuseppe La Torre, Luciana Caravatta, Adele Piscopo, Rosa Tambaro, Luigi Sofo, Giuseppina Sallustio, Marcello Ingrosso, Gabriella Macchia, Francesco Deodato, Vincenzo Picardi, Edy Ippolito, Numa Cellini, Vincenzo Valentini. (2010) A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer. Annals of Surgical Oncology 17:1, 194-205
CrossRef174
Juan Fabregat, Juli Busquets, Núria Peláez, Rosa Jorba, Francisco García-Borobia, Cristina Masuet, Carlos Valls, Sandra Ruiz-Osuna, Teresa Serrano, Maica Galán, María Cambray, Berta Laquente, Emilio Ramos, Antoni Rafecas. (2010) Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases. Cirugía Española (English Edition) 88:6, 374-382
CrossRef175
C.A.M. Sommerville, P. Limongelli, M. Pai, R. Ahmad, G. Stamp, N.A. Habib, R.C.N. Williamson, L.R. Jiao. (2009) Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: An analysis of clinicopathological factors. Journal of Surgical Oncology 100:8, 651-656
CrossRef176
Sameer Desai, Edgar Ben-Josef, Kent A. Griffith, Diane Simeone, Joel K. Greenson, Isaac R. Francis, Janet Hampton, Lisa Colletti, Alfred E. Chang, Theodore S. Lawrence, Mark M. Zalupski. (2009) Gemcitabine-Based Combination Chemotherapy Followed by Radiation With Capecitabine as Adjuvant Therapy for Resected Pancreas Cancer. International Journal of Radiation Oncology*Biology*Physics 75:5, 1450-1455
CrossRef177
T. Hackert, M. W. Büchler, J. Werner. (2009) Surgical management of pancreatic cancer – standard and extended resections. European Surgery 41:6, 293-299
CrossRef178
V. Heinemann. (2009) Current adjuvant and neoadjuvant treatment concepts in pancreatic cancer. European Surgery 41:6, 300-307
CrossRef179
Georg Pall. (2009) Pancreatic cancer – ASCO 2009. memo - Magazine of European Medical Oncology 2:4, 211-213
CrossRef180
Giuliano Barugola, Stefano Partelli, Stefano Marcucci, Nora Sartori, Paola Capelli, Claudio Bassi, Paolo Pederzoli, Massimo Falconi. (2009) Resectable Pancreatic Cancer: Who Really Benefits From Resection?. Annals of Surgical Oncology 16:12, 3316-3322
CrossRef181
Oliver Strobel, Thilo Hackert, Werner Hartwig, Frank Bergmann, Ulf Hinz, Moritz N. Wente, Stefan Fritz, Lutz Schneider, Markus W. Büchler, Jens Werner. (2009) Survival Data Justifies Resection for Pancreatic Metastases. Annals of Surgical Oncology 16:12, 3340-3349
CrossRef182
M. Kraft, P. Simon, A. Aghdassi, C. D. Heidecke, G. Sauter, J.-P. Kühn, F. U. Weiss, M. M. Lerch, J. Mayerle. (2009) Diagnostic workup of patients with pancreatic diseases. European Surgery 41:6, 268-279
CrossRef183
Michele Reni, S. Cereda, G. Balzano, P. Passoni, A. Rognone, A. Zerbi, R. Nicoletti, E. Mazza, P. G. Arcidiacono, V. Di Carlo, E. Villa. (2009) Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology 64:6, 1253-1259
CrossRef184
O. Mouaqit, F. Alami, M. Chourak, M. Ouanani, M. Absi, M. Echarrab, M. Amraoui, A. Errougani, R. Chkoff. (2009) Le cancer de la tête du pancréas vu aux urgences: aspects cliniques et thérapeutiques. Journal africain du cancer / African Journal of Cancer 1:4, 217-222
CrossRef185
Sreenivasa Chandana, Daruka Mahadevan. (2009) Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?. Expert Reviews in Molecular Medicine 11,
CrossRef186
Hidetoshi Eguchi, Osamu Ishikawa, Hiroaki Ohigashi, Hidenori Takahashi, Masayuki Ohue, Akemi Takenaka, Yasuhiko Tomita, Masahiko Yano. (2009) Real-time and the in vivo detection of minute cancer invasion to the portal-superior mesenteric vein using contact endoscopy during a pancreatic cancer resection. The American Journal of Surgery 198:5, e66-e71
CrossRef187
Desmond Yip, Christos Karapetis, Andrew Strickland, Christopher B Steer, David Goldstein, Karin L Dearness. 2009. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. .
CrossRef188
Robert C. Miller, Matthew J. Iott, Michele M. Corsini. (2009) Review of Adjuvant Radiochemotherapy for Resected Pancreatic Cancer and Results From Mayo Clinic for the 5th JUCTS Symposium. International Journal of Radiation Oncology*Biology*Physics 75:2, 364-368
CrossRef189
M.V. Williams, K.J. Drinkwater. (2009) Radiotherapy in England in 2007: Modelled Demand and Audited Activity. Clinical Oncology 21:8, 575-590
CrossRef190
Thilo Welsch, Shereen Keleg, Frank Bergmann, Luca Degrate, Sonja Bauer, Jan Schmidt. (2009) Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma. Clinical & Experimental Metastasis 26:7, 701-711
CrossRef191
H Ueno, T Kosuge, Y Matsuyama, J Yamamoto, A Nakao, S Egawa, R Doi, M Monden, T Hatori, M Tanaka, M Shimada, K Kanemitsu. (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. British Journal of Cancer 101:6, 908-915
CrossRef192
Fiona Campbell, Richard A Smith, Philip Whelan, Robert Sutton, Michael Raraty, John P Neoptolemos, Paula Ghaneh. (2009) Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 55:3, 277-283
CrossRef193
Dong Do You, Hyung Geun Lee, Jin Seok Heo, Seong Ho Choi, Dong Wook Choi. (2009) Prognostic Factors and Adjuvant Chemoradiation Therapy After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery 13:9, 1699-1706
CrossRef194
C.G. Willett, B.G. Czito. (2009) Chemoradiotherapy in Gastrointestinal Malignancies. Clinical Oncology 21:7, 543-556
CrossRef195
Dominik Tinkl, Gerhard G. Grabenbauer, Henriette Golcher, Thomas Meyer, Thomas Papadopoulos, Werner Hohenberger, Rolf Sauer, Thomas B. Brunner. (2009) Downstaging of Pancreatic Carcinoma after Neoadjuvant Chemoradiation. Strahlentherapie und Onkologie 185:9, 557-566
CrossRef196
J W Valle, H Wasan, P Johnson, E Jones, L Dixon, R Swindell, S Baka, A Maraveyas, P Corrie, S Falk, S Gollins, F Lofts, L Evans, T Meyer, A Anthoney, T Iveson, M Highley, R Osborne, J Bridgewater. (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study. British Journal of Cancer 101:4, 621-627
CrossRef197
Jona A. Hattangadi, Theodore S. Hong, Beow Y. Yeap, Harvey J. Mamon. (2009) Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer 115:16, 3640-3650
CrossRef198
Irene Banti, Susanna Nencetti, Elisabetta Orlandini, Annalina Lapucci, Maria Cristina Breschi, Stefano Fogli. (2009) Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. Journal of Pharmacy and Pharmacology 61:8, 1057-1066
CrossRef199
R. Le Scodan, F. Mornex, N. Girard, C. Mercier, P.-J. Valette, M. Ychou, F. Bibeau, P. Roy, J.-Y. Scoazec, C. Partensky. (2009) Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Annals of Oncology 20:8, 1387-1396
CrossRef200
Andrew V. Biankin, James G. Kench, Emily K. Colvin, Davendra Segara, Christopher J. Scarlett, Nam Q. Nguyen, David K. Chang, Adrienne L. Morey, C.–Soon Lee, Mark Pinese, Samuel C.L. Kuo, Johana M. Susanto, Peter H. Cosman, Geoffrey J. Lindeman, Jane E. Visvader, Tuan V. Nguyen, Neil D. Merrett, Janindra Warusavitarne, Elizabeth A. Musgrove, Susan M. Henshall, Robert L. Sutherland. (2009) Expression of S100A2 Calcium-Binding Protein Predicts Response to Pancreatectomy for Pancreatic Cancer. Gastroenterology 137:2, 558-568.e11
CrossRef201
Timothy N. Showalter, Atul S. Rao, P. Rani Anne, Francis E. Rosato, Ernest L. Rosato, Jocelyn Andrel, Terry Hyslop, Xia Xu, Adam C. Berger. (2009) Does Intraoperative Radiation Therapy Improve Local Tumor Control in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Adenocarcinoma? A Propensity Score Analysis. Annals of Surgical Oncology 16:8, 2116-2122
CrossRef202
Myriam Bouchard, Richard A. Amos, Tina M. Briere, Sam Beddar, Christopher H. Crane. (2009) Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiotherapy and Oncology 92:2, 238-243
CrossRef203
Jeffrey J. Meyer, Christopher H. Crane. (2009) Is There a Role for Intraoperative Radiation Therapy in Patients with Resected Pancreatic Adenocarcinoma?. Annals of Surgical Oncology 16:8, 2081-2083
CrossRef204
Reid B. Adams, Peter J. Allen. (2009) Surgical Treatment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Evans et al.. Annals of Surgical Oncology 16:7, 1745-1750
CrossRef205
Ross A. Abrams, Andrew M. Lowy, Eileen M. O’Reilly, Robert A. Wolff, Vincent J. Picozzi, Peter W. T. Pisters. (2009) Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement. Annals of Surgical Oncology 16:7, 1751-1756
CrossRef206
Werner Hartwig, Thilo Hackert, Ulf Hinz, Matthias Hassenpflug, Oliver Strobel, Markus W. Büchler, Jens Werner. (2009) Multivisceral Resection for Pancreatic Malignancies. Annals of Surgery 250:1, 81-87
CrossRef207
K F D Kuhlmann, M A van Geer, C T Bakker, J E M Dekker, M J E Havenga, R P J Oude Elferink, D J Gouma, P J Bosma, J G Wesseling. (2009) Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma. Cancer Gene Therapy 16:7, 585-597
CrossRef208
Jordan Berlin, John P. Hoffman, William F. Regine. (2009) Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference. Annals of Surgical Oncology 16:7, 1757-1759
CrossRef209
Hiroaki Ohigashi, Osamu Ishikawa, Hidetoshi Eguchi, Hidenori Takahashi, Kunihito Gotoh, Terumasa Yamada, Masahiko Yano, Akihiko Nakaizumi, Hiroyuki Uehara, Yoshihiko Tomita, Kinji Nishiyama. (2009) Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer. Annals of Surgery 250:1, 88-95
CrossRef210
Carolin Sorg, Jan Schmidt, Markus W. Büchler, Lutz Edler, Angela Märten. (2009) Examination of External Validity in Randomized Controlled Trials for Adjuvant Treatment of Pancreatic Adenocarcinoma. Pancreas 38:5, 542-550
CrossRef211
Ross Carter, Deborah D. Stocken, Payla Ghaneh, Simon R. Bramhall, Attila Olah, Deszo Kelemen, Claudio Bassi, Helmut Friess, Christo Dervenis, Nigel Spry, Markus W. Büchler, John P. Neoptolemos, . (2009) Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. International Journal of Cancer 124:12, 2960-2965
CrossRef212
Kimberly A. Vanderveen, Steven L. Chen, Daixin Yin, Rosemary D. Cress, Richard J. Bold. (2009) Benefit of postoperative adjuvant therapy for pancreatic cancer. Cancer 115:11, 2420-2429
CrossRef213
Nisha L. Jacobs, Florencia G. Que, Robert C. Miller, Santhi Swaroop Vege, Michael B. Farnell, Aminah Jatoi. (2009) Cumulative Morbidity and Late Mortality in Long-Term Survivors of Exocrine Pancreas Cancer. Journal of Gastrointestinal Cancer 40:1-2, 46-50
CrossRef214
J.K. Pine, K.G. Fusai, R. Young, D. Sharma, B.R. Davidson, K.V. Menon, S.H. Rahman. (2009) Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. European Journal of Surgical Oncology (EJSO) 35:6, 605-610
CrossRef215
Yukihiro Yokoyama, Yuji Nimura, Masato Nagino. (2009) Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies. Surgery Today 39:6, 466-475
CrossRef216
S. Cascinu, S. Jelic, . (2009) Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv37-iv40
CrossRef217
Manuel Hidalgo, Albert Abad, Enrique Aranda, Luis Díez, Jaime Feliu, Carlos Gómez, Antonio Irigoyen, Rafael López, Fernando Rivera, Carmen Rubio, Javier Sastre, Josep Tabernero, Eduardo Díaz-Rubio. (2009) Consensus on the treatment of pancreatic cancer in Spain. Clinical and Translational Oncology 11:5, 290-301
CrossRef218
Nipun B. Merchant, Jennifer Rymer, Elizabeth A.S. Koehler, G. Daniel Ayers, Jason Castellanos, David A. Kooby, Sharon H. Weber, Clifford S. Cho, C. Max Schmidt, Atilla Nakeeb, Jesus M. Matos, Charles R. Scoggins, Robert C.G. Martin, Hong Jin Kim, Syed A. Ahmad, Carrie K. Chu, Rebecca McClaine, Brian K. Bednarski, Charles A. Staley, Kenneth Sharp, Alexander A. Parikh. (2009) Adjuvant Chemoradiation Therapy for Pancreatic Adenocarcinoma: Who Really Benefits?. Journal of the American College of Surgeons 208:5, 829-838
CrossRef219
Marcia Bockbrader, Edward Kim. (2009) Role of intensity-modulated radiation therapy in gastrointestinal cancer. Expert Review of Anticancer Therapy 9:5, 637-647
CrossRef220
T.D.L. Crosby, M. Evans. (2009) The Management of Locally Advanced Carcinoma of the Oesophagus — SCOPE for Improvement?. Clinical Oncology 21:4, 281-284
CrossRef221
Richard A. Smith, Lorraine Bosonnet, Michael Raraty, Robert Sutton, John P. Neoptolemos, Fiona Campbell, Paula Ghaneh. (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. The American Journal of Surgery 197:4, 466-472
CrossRef222
Christine C. Olsen, Tracey E. Schefter, Honglin Chen, Madeleine Kane, Stephen Leong, Martin D. McCarter, Yang Chen, Philip Mack, S Gail Eckhardt, Greg Stiegmann, David Raben. (2009) Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation. American Journal of Clinical Oncology 32:2, 115-121
CrossRef223
Matthew H. G. Katz, Huamin Wang, Jason B. Fleming, Charlotte C. Sun, Rosa F. Hwang, Robert A. Wolff, Gauri Varadhachary, James L. Abbruzzese, Christopher H. Crane, Sunil Krishnan, Jean-Nicolas Vauthey, Eddie K. Abdalla, Jeffrey E. Lee, Peter W. T. Pisters, Douglas B. Evans. (2009) Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. Annals of Surgical Oncology 16:4, 836-847
CrossRef224
Sascha A. Müller, Mark Hartel, Arianeb Mehrabi, Thilo Welsch, David J. Martin, Ulf Hinz, Bruno M. Schmied, Markus W. Büchler. (2009) Vascular Resection in Pancreatic Cancer Surgery: Survival Determinants. Journal of Gastrointestinal Surgery 13:4, 784-792
CrossRef225
Bolanle Asiyanbola, Ana Gleisner, Joseph M. Herman, Michael A. Choti, Christopher L. Wolfgang, Michael Swartz, Barish H. Edil, Richard D. Schulick, John L. Cameron, Timothy M. Pawlik. (2009) Determining Pattern of Recurrence Following Pancreaticoduodenectomy and Adjuvant 5-Flurouracil-Based Chemoradiation Therapy: Effect of Number of Metastatic Lymph Nodes and Lymph Node Ratio. Journal of Gastrointestinal Surgery 13:4, 752-759
CrossRef226
Sohei Satoi, Hiroaki Yanagimoto, Hideyoshi Toyokawa, Kanji Takahashi, Yoichi Matsui, Hiroaki Kitade, Hynek Mergental, Noboru Tanigawa, Soichiro Takai, A-Hon Kwon. (2009) Surgical Results After Preoperative Chemoradiation Therapy for Patients With Pancreatic Cancer. Pancreas 38:3, 282-288
CrossRef227
Isao Kurosaki, Yasuyuki Kawachi, Koei Nihei, Yoshiaki Tsuchiya, Takashi Aono, Naoyuki Yokoyama, Takeaki Shimizu, Katsuyoshi Hatakeyama. (2009) Liver Perfusion Chemotherapy With 5-Fluorouracil Followed by Systemic Gemcitabine Administration for Resected Pancreatic Cancer. Pancreas 38:2, 161-167
CrossRef228
Masaji Tani, Manabu Kawai, Motoki Miyazawa, Seiko Hirono, Shinomi Ina, Ryohei Nishioka, Yoichi Fujita, Kazuhisa Uchiyama, Hiroki Yamaue. (2009) Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbeck's Archives of Surgery 394:2, 249-253
CrossRef229
Andrew Weickhardt, Michael Michael. (2009) Pancreatic cancer: advances in medical therapy. Expert Review of Clinical Pharmacology 2:2, 173-180
CrossRef230
Félix Lluís. (2009) ¿Quimioterapia, quimiorradioterapia u observación tras la resección completa de un adenocarcinoma pancreático?. Gastroenterología y Hepatología 32:2, 120-121
CrossRef231
C. Timke, J.P. Debus. (2009) Die Rolle der Strahlentherapie bei der Behandlung des Pankreaskarzinoms aus der Sicht des Radioonkologen. Der Radiologe 49:2, 149-153
CrossRef232
L. Grenacher, M. Klauß. (2009) Computertomographie bei Pankreastumoren. Der Radiologe 49:2, 107-123
CrossRef233
Kimberly M. Brown. (2009) Multidisciplinary Approach to Tumors of the Pancreas and Biliary Tree. Surgical Clinics of North America 89:1, 115-131
CrossRef234
M. Loos, H. Friess, J. Kleeff. (2009) Chirurgie maligner Pankreastumoren. Der Radiologe 49:2, 137-143
CrossRef235
J P Neoptolemos, D D Stocken, C Tudur Smith, C Bassi, P Ghaneh, E Owen, M Moore, R Padbury, R Doi, D Smith, M W Büchler. (2009) Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. British Journal of Cancer 100:2, 246-250
CrossRef236
Ruchika Gutt, Stanley L Liauw, Ralph R Weichselbaum. (2009) Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?. Nature Clinical Practice Gastroenterology & Hepatology 6:1, 38-46
CrossRef237
John S. Moody, Stephen M. Sawrie, Kevin R. Kozak, John P. Plastaras, George Howard, James A. Bonner. (2009) Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients. Journal of Gastroenterology 44:1, 84-91
CrossRef238
Andrew H. Ko, Margaret A. Tempero. (2009) Personalized Medicine for Pancreatic Cancer: A Step in the Right Direction. Gastroenterology 136:1, 43-45
CrossRef239
Yasmin Issa, Daniel Nummer, Tobias Seibel, Susanne Sebens Müerköster, Moritz Koch, Friedrich-Hubertus Schmitz-Winnenthal, Luis Galindo, Juergen Weitz, Philipp Beckhove, Peter Altevogt. (2009) Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. Journal of Molecular Medicine 87:1, 99-112
CrossRef240
Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasuo Hayashidani, Yasushi Hashimoto, Hiroki Ohge, Taijiro Sueda. (2009) Impact of Adjuvant Gemcitabine Plus S-1 Chemotherapy After Surgical Resection for Adenocarcinoma of the Body or Tail of the Pancreas. Journal of Gastrointestinal Surgery 13:1, 85-92
CrossRef241
G. APRILE, A. SOBRERO. (2009) Highlights from the 2008 Gastrointestinal Cancers Symposium. European Journal of Cancer Care 18:1, 10-17
CrossRef242
N. Iqbal, R.E. Lovegrove, H.S. Tilney, A.T. Abraham, S. Bhattacharya, P.P. Tekkis, H.M. Kocher. (2009) A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy: A meta-analysis of 1909 patients. European Journal of Surgical Oncology (EJSO) 35:1, 79-86
CrossRef243
W. Hartwig, L. Schneider, M. K. Diener, F. Bergmann, M. W. Büchler, J. Werner. (2009) Preoperative tissue diagnosis for tumours of the pancreas. British Journal of Surgery 96:1, 5-20
CrossRef244
Michio Ueda, Itaru Endo, Masayuki Nakashima, Yuta Minami, Kazuhisa Takeda, Kenichi Matsuo, Yasuhiko Nagano, Kuniya Tanaka, Yasushi Ichikawa, Shinji Togo, Chikara Kunisaki, Hiroshi Shimada. (2009) Prognostic Factors After Resection of Pancreatic Cancer. World Journal of Surgery 33:1, 104-110
CrossRef245
N Spry, S Bydder, J Harvey, M Borg, S Ngan, J Millar, P Graham, Y Zissiadis, A Kneebone, M Ebert. (2008) Accrediting radiation technique in a multicentre trial of chemoradiation for pancreatic cancer. Journal of Medical Imaging and Radiation Oncology 52:6, 598-604
CrossRef246
Stefan Heinrich, Markus Schäfer, Achim Weber, Thomas F. Hany, Ujwal Bhure, Bernhard C. Pestalozzi, Pierre-Alain Clavien. (2008) Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity. Annals of Surgery 248:6, 1014-1022
CrossRef247
G. Pall. (2008) Pancreatic cancer. memo - Magazine of European Medical Oncology 1:4, 259-262
CrossRef248
R. Longo, F. Cacciamani, G. Naso, G. Gasparini. (2008) Pancreatic cancer: From molecular signature to target therapy. Critical Reviews in Oncology/Hematology 68:3, 197-211
CrossRef249
Marjolein J. M. Morak, Ate van der Gaast, Luca Incrocci, Herman van Dekken, John J. Hermans, Johannes Jeekel, Wim C. J. Hop, Geert Kazemier, Casper H. J. van Eijck. (2008) Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer. Annals of Surgery 248:6, 1031-1041
CrossRef250
Romuald Le Scodan, Françoise Mornex, Christian Partensky, Catherine Mercier, Pierre-Jean Valette, Marc Ychou, Pascal Roy, Jean-Yves Scoazec. (2008) Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 31:6, 545-552
CrossRef251
Ryuichiro Doi, Masayuki Imamura, Ryo Hosotani, Toshihide Imaizumi, Takashi Hatori, Ken Takasaki, Akihiro Funakoshi, Hideyuki Wakasugi, Takehide Asano, Shoichi Hishinuma, Yoshiro Ogata, Makoto Sunamura, Koji Yamaguchi, Masao Tanaka, Sonshin Takao, Takashi Aikou, Koichi Hirata, Hiroyuki Maguchi, Koichi Aiura, Tatsuya Aoki, Akira Kakita, Makoto Sasaki, Masahiko Ozaki, Satoru Matsusue, Shunichi Higashide, Hideki Noda, Seiyo Ikeda, Shunzo Maetani, Shigeaki Yoshida, . (2008) Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: Final results of a randomized multi-institutional trial. Surgery Today 38:11, 1021-1028
CrossRef252
Alexander M. Stessin, Joshua E. Meyer, David L. Sherr. (2008) Neoadjuvant Radiation Is Associated With Improved Survival in Patients With Resectable Pancreatic Cancer: An Analysis of Data From the Surveillance, Epidemiology, and End Results (SEER) Registry. International Journal of Radiation Oncology*Biology*Physics 72:4, 1128-1133
CrossRef253
Hideyuki Yoshitomi, Akira Togawa, Fumio Kimura, Hiroshi Ito, Hiroaki Shimizu, Hiroyuki Yoshidome, Masayuki Otsuka, Atsushi Kato, Satoshi Nozawa, Katsunori Furukawa, Masaru Miyazaki, . (2008) A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 113:9, 2448-2456
CrossRef254
Satoru Seo, Ryuichiro Doi, Takafumi Machimoto, Kazuhiro Kami, Toshihiko Masui, Etsuro Hatano, Kohei Ogawa, Tatsuya Higashi, Shinji Uemoto. (2008) Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery 15:6, 634-639
CrossRef255
Mustapha Adham, Daniel Jaeck, Joël Le Borgne, Elie Oussoultzouglou, Marie-Pierre Chenard-Neu, Jean-François Mosnier, Jean-Yves Scoazec, Françoise Mornex, Christian Partensky. (2008) Long-Term Survival (5-20 Years) After Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Pancreas 37:4, 352-357
CrossRef256
D. Bogoevski, T. Strate, E. F. Yekebas, J. R. Izbicki. (2008) Pancreatic cancer: a generalized disease—prognostic impact of cancer cell dissemination. Langenbeck's Archives of Surgery 393:6, 911-917
CrossRef257
N. Iqbal, R.E. Lovegrove, H.S. Tilney, A.T. Abraham, S. Bhattacharya, P.P. Tekkis, H.M. Kocher. (2008) A comparison of pancreaticoduodenectomy with pylorus preserving pancreaticoduodenectomy: A meta-analysis of 2822 patients. European Journal of Surgical Oncology (EJSO) 34:11, 1237-1245
CrossRef258
Saima Sharif, Ramesh K. Ramanathan, Douglas Potter, Kathleen Cieply, Alyssa M. Krasinskas. (2008) HER2 Gene Amplification and Chromosome 17 Copy Number Do Not Predict Survival of Patients with Resected Pancreatic Adenocarcinoma. Digestive Diseases and Sciences 53:11, 3026-3032
CrossRef259
X H Shi, Z Y Liang, X Y Ren, T H Liu. (2008) Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Therapy
CrossRef260
R Hennig, T Osman, I Esposito, N Giese, S M Rao, X-Z Ding, W-G Tong, M W Büchler, T Yokomizo, H Friess, T E Adrian. (2008) BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. British Journal of Cancer 99:7, 1064-1073
CrossRef261
Gary Middleton, Paula Ghaneh, Eithne Costello, William Greenhalf, John P Neoptolemos. (2008) New treatment options for advanced pancreatic cancer. Expert Review of Gastroenterology & Hepatology 2:5, 673-696
CrossRef262
Robert A. Wolff, Gauri R. Varadhachary, Douglas B. Evans. (2008) Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress. Annals of Surgical Oncology 15:10, 2773-2786
CrossRef263
Timothy J. Kinsella, Yuji Seo, Joseph Willis, Thomas A. Stellato, Christopher T. Siegel, Deborah Harpp, James K. Willson, Joseph Gibbons, Juan R. Sanabria, Jeffrey M. Hardacre, James P. Schulak. (2008) The Impact of Resection Margin Status and Postoperative CA19-9 Levels on Survival and Patterns of Recurrence After Postoperative High-Dose Radiotherapy With 5-FU—Based Concurrent Chemotherapy for Resectable Pancreatic Cancer. American Journal of Clinical Oncology 31:5, 446-453
CrossRef264
Maki Yamamoto, David K Imagawa, Matthew HG Katz. (2008) Multidisciplinary management of resectable adenocarcinoma of the pancreatic head. Expert Review of Anticancer Therapy 8:10, 1611-1621
CrossRef265
Verena Schick, Christiane Franzius, Torsten Beyna, May Lin Oei, Jürgen Schnekenburger, Matthias Weckesser, Wolfram Domschke, Otmar Schober, Walter Heindel, Thorsten Pohle, Kai Uwe Juergens. (2008) Diagnostic impact of 18F-FDG PET–CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. European Journal of Nuclear Medicine and Molecular Imaging 35:10, 1775-1785
CrossRef266
N Starling, D Cunningham. (2008) Survival from cancer of the pancreas in England and Wales up to 2001. British Journal of Cancer 99, S24-S25
CrossRef267
C W Michalski, M Erkan, D Sauliunaite, T Giese, R Stratmann, C Sartori, N A Giese, H Friess, J Kleeff. (2008) Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. British Journal of Cancer 99:5, 760-767
CrossRef268
M.A. Hawkins, D. Tait. (2008) Locally Advanced Non-Metastatic Pancreatic Cancer — Can We Do More?. Clinical Oncology 20:7, 532-534
CrossRef269
Martin Loos, Nathalia A. Giese, Jörg Kleeff, Thomas Giese, Matthias M. Gaida, Frank Bergmann, Melanie Laschinger, Markus W.Büchler, Helmut Friess. (2008) Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Letters 268:1, 98-109
CrossRef270
Jens Werner, Markus W. Büchler. (2008) Pankreaskarzinom: Historie und Einführung in die Thematik. Onkopipeline 1:2, 49-51
CrossRef271
Hideki Ueno, Tomoo Kosuge. (2008) Adjuvant treatments for resectable pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery 15:5, 468-472
CrossRef272
Marc W. Münter, Alexandra D. Jensen, Robert Krempien, Jürgen Debus. (2008) Aktuelle radioonkologische Konzepte in der Behandlung des Adenokarzinoms des Pankreas. Onkopipeline 1:2, 69-73
CrossRef273
Anne Katrin Berger, Dirk Jäger. (2008) Systemtherapie des Pankreaskarzinoms. Onkopipeline 1:2, 74-77
CrossRef274
Yifan Zhu, Igor Tibensky, Jan Schmidt, Eduard Ryschich, Angela Märten. (2008) Interferon-α Enhances Antitumor Effect of Chemotherapy in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma. Journal of Immunotherapy 31:7, 599-606
CrossRef275
S. Mukherjee, E. Hudson, S. Reza, M. Thomas, T. Crosby, T. Maughan. (2008) Pancreatic Cancer within a UK Cancer Network with Special Emphasis on Locally Advanced Non-metastatic Pancreatic Cancer. Clinical Oncology 20:7, 535-540
CrossRef276
Andrew M. Lowy. (2008) Neoadjuvant Therapy for Pancreatic Cancer. Journal of Gastrointestinal Surgery 12:9, 1600-1608
CrossRef277
M.P. Lutz, S. Pourebrahim. (2008) Pankreaskarzinom. Der Internist 49:9, 1079-1088
CrossRef278
Jeffrey M. Farma, Alfredo A. Santillan, Marcovalerio Melis, Janet Walters, Daly Belinc, Dung-Tsa Chen, Edward A. Eikman, Mokenge Malafa. (2008) PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms. Annals of Surgical Oncology 15:9, 2465-2471
CrossRef279
Stefan Fritz, Jens Werner, Werner Hartwig. (2008) Multimodales interdisziplinäres Therapiekonzept des duktalen Pankreaskarzinoms. Onkopipeline 1:2, 52-56
CrossRef280
Martin Loos, Jörg Kleeff, Helmut Friess, Markus W. Büchler. (2008) Surgical Treatment of Pancreatic Cancer. Annals of the New York Academy of Sciences 1138:1, 169-180
CrossRef281
Avo Artinyan, Joseph Kim. (2008) Reply to Improved Survival With Adjuvant External-Beam Radiation Therapy in Lymph Node-Negative Pancreatic Cancer. Cancer 113:5, 1111-1112
CrossRef282
David C. Linehan, Marcus C. B. Tan, Steven M. Strasberg, Jeffrey A. Drebin, William G. Hawkins, Joel Picus, Robert J. Myerson, Robert S. Malyapa, Michael Hull, Kathryn Trinkaus, Benjamin R. Tan. (2008) Adjuvant Interferon-based Chemoradiation Followed By Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study. Annals of Surgery 248:2, 145-151
CrossRef283
Lisa J Hazard, Jonathan D Tward, Dennis C Shrieve. (2008) Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer. Nature Clinical Practice Oncology 5:8, 438-439
CrossRef284
Felix Y Feng, Edgar Ben-Josef. (2008) Radiation therapy improves survival in patients with pancreatic adenocarcinoma. Nature Clinical Practice Oncology 5:8, 434-435
CrossRef285
Sabrina Irmscher, Norbert Senninger, Christina Schleicher. (2008) Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer. Annals of Surgical Oncology 15:7, 2059-2060
CrossRef286
David K Chang, Neil D Merrett, Andrew V Biankin, . (2008) Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem?. Journal of Gastroenterology and Hepatology 23:7pt1, 1036-1045
CrossRef287
Chiara Pierantoni, Alessandra Pagliacci, Mario Scartozzi, Rossana Berardi, Maristella Bianconi, Stefano Cascinu. (2008) Pancreatic cancer: Progress in cancer therapy. Critical Reviews in Oncology/Hematology 67:1, 27-38
CrossRef288
H. Golcher, T. Brunner, G. Grabenbauer, S. Merkel, T. Papadopoulos, W. Hohenberger, T. Meyer. (2008) Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. European Journal of Surgical Oncology (EJSO) 34:7, 756-764
CrossRef289
Dirk J. Gouma, Olivier R.C. Busch, Thomas M. van Gulik. (2008) Treatment of Pancreatic Adenocarcinoma: A European Perspective. Surgical Oncology Clinics of North America 17:3, 569-586
CrossRef290
Jeannine Bachmann, Mathias Heiligensetzer, Holger Krakowski-Roosen, Markus W. Büchler, Helmut Friess, Marc E. Martignoni. (2008) Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer. Journal of Gastrointestinal Surgery 12:7, 1193-1201
CrossRef291
Kyle C. Cuneo, Ling Geng, Allie Fu, Darren Orton, Dennis E. Hallahan, Anuradha Bapsi Chakravarthy. (2008) SU11248 (Sunitinib) Sensitizes Pancreatic Cancer to the Cytotoxic Effects of Ionizing Radiation. International Journal of Radiation Oncology*Biology*Physics 71:3, 873-879
CrossRef292
Caio M. Rocha-Lima. (2008) New directions in the management of advanced pancreatic cancer: a review. Anti-Cancer Drugs 19:5, 435-446
CrossRef293
Yixing Jiang, Eric T Kimchi, Alberto J Montero, Kevin F Staveley-O’Carroll, Jaffer A Ajani. (2008) Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer Therapy 8:6, 975-991
CrossRef294
Felipe A. Calvo, Vincenzo Valentini. (2008) Radiotherapy for pancreatic cancer: Systematic nihilism or intraoperative realism. Radiotherapy and Oncology 87:3, 314-317
CrossRef295
Irene Esposito, Jörg Kleeff, Frank Bergmann, Caroline Reiser, Esther Herpel, Helmut Friess, Peter Schirmacher, Markus W. Büchler. (2008) Most Pancreatic Cancer Resections are R1 Resections. Annals of Surgical Oncology 15:6, 1651-1660
CrossRef296
Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasuo Hayashidani, Yasushi Hashimoto, Naoya Nakagawa, Hiroki Ohge, Taijiro Sueda. (2008) Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. The American Journal of Surgery 195:6, 757-762
CrossRef297
B. Chauffert, F. Mornex, F. Bonnetain, P. Rougier, C. Mariette, O. Bouche, J. F. Bosset, T. Aparicio, L. Mineur, A. Azzedine, P. Hammel, J. Butel, N. Stremsdoerfer, P. Maingon, L. Bedenne. (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Annals of Oncology 19:9, 1592-1599
CrossRef298
Martin Loos, Jörg Kleeff, Helmut Friess, Markus W. Büchler. (2008) Approaches to localized pancreatic cancer. Current Oncology Reports 10:3, 212-219
CrossRef299
Jeffrey John Meyer, Christopher George Willett, Brian Gary Czito. (2008) Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?. Future Oncology 4:2, 241-255
CrossRef300
M.T. Seymour, I. Trigonis, P.J. Finan, F. Halstead, R. Dunham, G. Wilson, D. Farrugia, J.D. Chester, J. King, C.B. Brown, M.L. Slevin, S.P. Joel. (2008) A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. European Journal of Surgical Oncology (EJSO) 34:4, 403-409
CrossRef301
Vincent J. Picozzi, Peter W. T. Pisters, Selwyn M. Vickers, Steven M. Strasberg. (2008) Strength of the Evidence: Adjuvant Therapy for Resected Pancreatic Cancer. Journal of Gastrointestinal Surgery 12:4, 657-661
CrossRef302
C. M. Halloran, P. Ghaneh, S. Connor, R. Sutton, J. P. Neoptolemos, M. G. T. Raraty. (2008) Carbohydrate antigen 19·9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. British Journal of Surgery 95:4, 453-459
CrossRef303
Jaswinder S. Samra, Sivakumar Gananadha, Thomas J. Hugh. (2008) SURGICAL MANAGEMENT OF CARCINOMA OF THE HEAD OF PANCREAS: EXTENDED LYMPHADENECTOMY OR MODIFIED EN BLOC RESECTION?. ANZ Journal of Surgery 78:4, 228-236
CrossRef304
Nigel Spry, Jennifer Harvey, Craig MacLeod, Martin Borg, Samuel Y. Ngan, Jeremy L. Millar, Peter Graham, Yvonne Zissiadis, Andrew Kneebone, Susan Carroll, Terri Davies, William H.H. Reece, Barry Iacopetta, David Goldstein. (2008) 3D Radiotherapy Can Be Safely Combined With Sandwich Systemic Gemcitabine Chemotherapy in the Management of Pancreatic Cancer: Factors Influencing Outcome. International Journal of Radiation Oncology*Biology*Physics 70:5, 1438-1446
CrossRef305
Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasuo Hayashidani, Yasushi Hashimoto, Hiroki Ohge, Taijiro Sueda. (2008) Postoperative Adjuvant Chemotherapy Improves Survival after Surgical Resection for Pancreatic Carcinoma. Journal of Gastrointestinal Surgery 12:3, 534-541
CrossRef306
V. Heinemann. (2008) Future perspectives in the treatment of pancreatic cancer. memo - Magazine of European Medical Oncology 1:1, 27-30
CrossRef307
Regina V. Tse, Laura A. Dawson, Alice Wei, Malcolm Moore. (2008) Neoadjuvant treatment for pancreatic cancer—A review. Critical Reviews in Oncology/Hematology 65:3, 263-274
CrossRef308
P. Ghaneh, R. Smith, C. Tudor-Smith, M. Raraty, J.P. Neoptolemos. (2008) Neoadjuvant and adjuvant strategies for pancreatic cancer. European Journal of Surgical Oncology (EJSO) 34:3, 297-305
CrossRef309
Sarah E. Greer, J. Marc Pipas, John E. Sutton, Bassem I. Zaki, Michael Tsapakos, Thomas A. Colacchio, Jennifer J. Gibson, Daniel C. Wiener, Gregory H. Ripple, Richard J. Barth. (2008) Effect of Neoadjuvant Therapy on Local Recurrence after Resection of Pancreatic Adenocarcinoma. Journal of the American College of Surgeons 206:3, 451-457
CrossRef310
Einar Björnsson, Jonas Gustafsson, Jakob Borkman, Anders Kilander. (2008) Fate of patients with obstructive jaundice. Journal of Hospital Medicine 3:2, 117-123
CrossRef311
John S. Moody, Stephen M. Sawrie, Kevin R. Kozak, John P. Plastaras, George Howard, James A. Bonner. (2008) Stage-Specific Survival Differences Associated with Postoperative Radiotherapy for Gastrointestinal Cancers. Journal of Gastrointestinal Cancer 39:1-4, 86-99
CrossRef312
Thomas Schnelldorfer, Adam L. Ware, Michael G. Sarr, Thomas C. Smyrk, Lizhi Zhang, Rui Qin, Rachel E. Gullerud, John H. Donohue, David M. Nagorney, Michael B. Farnell. (2008) Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma. Annals of Surgery 247:3, 456-462
CrossRef313
Michael W. Müller, Helmut Friess, Jörg Köninger, David Martin, Moritz N. Wente, Ulf Hinz, Güralp O. Ceyhan, Pavel Blaha, Jörg Kleeff, Markus W. Büchler. (2008) Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. The American Journal of Surgery 195:2, 221-228
CrossRef314
Emre F. Yekebas, Dean Bogoevski, Guellue Cataldegirmen, Christina Kunze, Andreas Marx, Yogesh K. Vashist, Paulus G. Schurr, Lena Liebl, Sabrina Thieltges, Karim A. Gawad, Claus Schneider, Jakob R. Izbicki. (2008) En Bloc Vascular Resection for Locally Advanced Pancreatic Malignancies Infiltrating Major Blood Vessels. Annals of Surgery 247:2, 300-309
CrossRef315
Mitchell C. Coleman, Carla R. Asbury, David Daniels, Juan Du, Nukhet Aykin-Burns, Brian J. Smith, Ling Li, Douglas R. Spitz, Joseph J. Cullen. (2008) 2-Deoxy-d-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radical Biology and Medicine 44:3, 322-331
CrossRef316
Dan S. Zuckerman, David P. Ryan. (2008) Adjuvant therapy for pancreatic cancer. Cancer 112:2, 243-249
CrossRef317
Toshiyuki YAMAMOTO, Akihiko HORIGUCHI, Shin ISHIHARA, Masahiro ITO, Hideo NAGATA, Yukio ASANO, Kazuki TSUDA, Satoko MORIGAKI, Masahiro SHIMURA, Shuichi MIYAKAWA. (2008) A case report: Curatively resected locally advanced pancreatic head cancer by improvement of extrapancreatic nerve plexus invasion with gemcitabine-based chemoradiotherapy. Suizo 23:4, 525-532
CrossRef318
Andrea Mambrini, Claudio Bassi, Paola Pacetti, Tito Torri, Calogero Iacono, Michela Ballardini, Massimo Orlandi, Stefano Guadagni, Giammaria Fiorentini, Maurizio Cantore. (2008) Prognostic Factors in Patients With Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Chemotherapy. Pancreas 36:1, 56-60
CrossRef319
Sean P. Dineen, Christina L. Roland, Roderich E. Schwarz. (2008) Pancreatoduodenectomy with or without Pyloric Preservation: A Clinical Outcomes Comparison. HPB Surgery 2008, 1-8
CrossRef320
Avo Artinyan, Minia Hellan, Pablo Mojica-Manosa, Yi-Jen Chen, Richard Pezner, Joshua D. I. Ellenhorn, Joseph Kim. (2008) Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer. Cancer 112:1, 34-42
CrossRef321
Hirozumi Sawai, Yuji Okada, Hitoshi Funahashi, Hiroki Takahashi, Yoichi Matsuo, Akira Yasuda, Nobuo Ochi, Hiromitsu Takeyama, Tadao Manabe. (2008) Basement Membrane Proteins Play an Important Role in the Invasive Processes of Human Pancreatic Cancer Cells. Journal of Surgical Research 144:1, 117-123
CrossRef322
Yifan Zhu, Igor Tibensky, Jan Schmidt, Thilo Hackert, Eduard Ryschich, Dirk Jäger, Markus W. Büchler, Angela Märten. (2008) Interferon-α in Combination With Chemotherapy has Potent Antiangiogenic Properties in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma. Journal of Immunotherapy 31:1, 28-33
CrossRef323
R.A. Smith, L. Bosonnet, P. Ghaneh, M. Raraty, R. Sutton, F. Campbell, J.P. Neoptolemos. (2008) Preoperative CA19-9 Levels and Lymph Node Ratio Are Independent Predictors of Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Digestive Surgery 25:3, 226-232
CrossRef324
Sylvie Negrier, David Perol, Alain Ravaud, Christine Chevreau, Jacques-Olivier Bay, Remy Delva, Emmanuel Sevin, Armelle Caty, Bernard Escudier, . (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Cancer 110:11, 2448-2457
CrossRef325
Michel Ducreux, Valérie Boige, Diane Goéré, Eric Deutsch, Patrick Ezra, Dominique Elias, David Malka. (2007) Pancreatic cancer: From pathogenesis to cure. Best Practice & Research Clinical Gastroenterology 21:6, 997-1014
CrossRef326
Michael W. Müller, Helmut Friess, Jörg Kleeff, Rolf Dahmen, Markus Wagner, Ulf Hinz, Daniela Breisch-Girbig, Güralp O. Ceyhan, Markus W. Büchler. (2007) Is There Still a Role for Total Pancreatectomy?. Annals of Surgery 246:6, 966-975
CrossRef327
G. Wichert, T. Seufferlein. (2007) Adjuvante Chemotherapie bei soliden Tumoren des Gastrointestinaltrakts. Der Internist 48:12, 1335-1342
CrossRef328
Masaji Tani, Manabu Kawai, Hiroshi Terasawa, Shinomi Ina, Seiko Hirono, Tetsuya Shimamoto, Motoki Miyazawa, Kazuhisa Uchiyama, Hiroki Yamaue. (2007) Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery 14:6, 545-550
CrossRef329
Lisa Hazard, Jonathan D Tward, Aniko Szabo, Dennis C Shrieve. (2007) Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: Results of a study from the surveillance, epidemiology, and end results (SEER) registry data. Cancer 110:10, 2191-2201
CrossRef330
C. Reissfelder, M. Koch, M.W. Büchler, J. Weitz. (2007) Pankreaskarzinom. Der Chirurg 78:11, 1059-1072
CrossRef331
Karl Y. Bilimoria, David J. Bentrem, James S. Tomlinson, Ryan P. Merkow, Andrew K. Stewart, Clifford Y. Ko, Jay B. Prystowsky, Mark S. Talamonti. (2007) Quality of pancreatic cancer care at Veterans Administration compared with non-Veterans Administration hospitals. The American Journal of Surgery 194:5, 588-593
CrossRef332
Hans G. Smeenk, Casper H. J. van Eijck, Wim C. Hop, Joris Erdmann, Kheetje C. K. Tran, Muriel Debois, Eric van Cutsem, Herman van Dekken, Jean H. Klinkenbijl, Johannes Jeekel. (2007) Long-term Survival and Metastatic Pattern of Pancreatic and Periampullary Cancer After Adjuvant Chemoradiation or Observation. Annals of Surgery 246:5, 734-740
CrossRef333
Rebecca Kristeleit, Yujo Chua, David Cunningham. 2007. Multidisciplinary Team Management of Upper Gastrointestinal, Hepatic, Pancreatic, and Biliary Cancers. .
CrossRef334
Paula Ghaneh, John Neoptolemos. (2007) Adjuvant chemotherapy—the standard after resection for pancreatic cancer. The American Journal of Surgery 194:4, S131-S137
CrossRef335
Peter Büchler, Helmut Friess, Michael Müller, Jaber AlKhatib, Markus W. Büchler. (2007) Survival benefit of extended resection in pancreatic cancer. The American Journal of Surgery 194:4, S120-S126
CrossRef336
Juan F. Ruiz-Rabelo, Reyes Vázquez, María D. Perea, Adolfo Cruz, Raul González, Ana Romero, María C. Muñoz-Villanueva, Isaac Túnez, Pedro Montilla, Jordi Muntané, Francisco Javier Padillo. (2007) Beneficial properties of melatonin in an experimental model of pancreatic cancer. Journal of Pineal Research 43:3, 270-275
CrossRef337
Jamael El Fitori, Yun Su, Peter Büchler, Roman Ludwig, Nathalia A. Giese, Markus W. Büchler, Hilmar Quentmeier, Oscar J. Hines, Ingrid Herr, Helmut Friess. (2007) PKC 412 small-molecule tyrosine kinase inhibitor. Cancer 110:7, 1457-1468
CrossRef338
G. CAPURSO, H. J. SCHÜNEMANN, I. TERRENATO, A. MORETTI, M. KOCH, P. MUTI, L. CAPURSO, G. DELLE FAVE. (2007) Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Alimentary Pharmacology & Therapeutics 26:8, 1089-1099
CrossRef339
Angela Märten, Markus W. Büchler, Jan Schmidt. (2007) Radiochemoimmunotherapy for pancreatic cancer. The American Journal of Surgery 194:4, S138-S142
CrossRef340
Kyaw L Aung, David B Smith, JP Neoptolemos. (2007) Adjuvant therapy for pancreatic cancer. Expert Opinion on Pharmacotherapy 8:15, 2533-2541
CrossRef341
Joris Erdmann, Casper H.J. van Eijck, Johannes Jeekel. (2007) Standard resection of pancreatic cancer and the chance for cure. The American Journal of Surgery 194:4, S104-S109
CrossRef342
Markus W. Büchler, Jörg Kleeff, Helmut Friess. (2007) Surgical Treatment of Pancreatic Cancer. Journal of the American College of Surgeons 205:4, S81-S86
CrossRef343
Emery L. Chen, Richard A. Prinz. (2007) Long-term survival after pancreatic cancer treatment. The American Journal of Surgery 194:4, S127-S130
CrossRef344
A. Yazar, Z. Üstüner, B. Şakar, E. Kaytan Sağlam, H. Çamlıca, F. Aykan. (2007) Adjuvant chemoradiation for patients with adenocarcinoma of the pancreas: an expirence of single institute. Medical Oncology 24:4, 384-387
CrossRef345
Karl Y. Bilimoria, David J. Bentrem, Clifford Y. Ko, James S. Tomlinson, Andrew K. Stewart, David P. Winchester, Mark S. Talamonti. (2007) Multimodality therapy for pancreatic cancer in the U.S.. Cancer 110:6, 1227-1234
CrossRef346
Björn-Christian Link, Uta Reichelt, Matthias Schreiber, Jussuf T. Kaifi, Robin Wachowiak, Dean Bogoevski, Michael Bubenheim, Guel Cataldegirmen, Karim A. Gawad, Rana Issa, Susann Koops, Jakob R. Izbicki, Emre F. Yekebas. (2007) Prognostic Implications of Netrin-1 Expression and Its Receptors in Patients with Adenocarcinoma of the Pancreas. Annals of Surgical Oncology 14:9, 2591-2599
CrossRef347
J. Kleeff, C.W. Michalski, H. Friess, M.W. Büchler. (2007) Surgical treatment of pancreatic cancer: The role of adjuvant and multimodal therapies. European Journal of Surgical Oncology (EJSO) 33:7, 817-823
CrossRef348
D. Fitzsimmons, C. Osmond, S. George, C. D. Johnson. (2007) Trends in stomach and pancreatic cancer incidence and mortality in England and Wales, 1951-2000. British Journal of Surgery 94:9, 1162-1171
CrossRef349
Hans G Beger, Bettina M Rau. (2007) New advances in pancreatic surgery. Current Opinion in Gastroenterology 23:5, 522-534
CrossRef350
M.W. Büchler. (2007) Current management of localised pancreatic cancer. European Journal of Cancer Supplements 5:5, 418-419
CrossRef351
G Saraga, A Mafficini, P Ghaneh, C Sorio, E Costello. (2007) Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. Cancer Gene Therapy 14:9, 781-790
CrossRef352
Akira Togawa, Hideyuki Yoshitomi, Hiroshi Ito, Fumio Kimura, Hiroaki Shimizu, Masayuki Ohtsuka, Hiroyuki Yoshidome, Atsushi Kato, Shigeaki Sawada, Masaru Miyazaki. (2007) Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. International Journal of Clinical Oncology 12:4, 268-273
CrossRef353
Jörg Kleeff, Philipp Beckhove, Irene Esposito, Stephan Herzig, Peter E. Huber, J. Matthias Löhr, Helmut Friess. (2007) Pancreatic cancer microenvironment. International Journal of Cancer 121:4, 699-705
CrossRef354
Edward B. Garon, David Sawcer, P. Thomas Vernier, Tao Tang, Yinghua Sun, Laura Marcu, Martin A. Gundersen, H. Phillip Koeffler. (2007) In vitro andin vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. International Journal of Cancer 121:3, 675-682
CrossRef355
Mary F. Mulcahy. (2007) Adjuvant Therapy for Pancreas Cancer: Advances and Controversies. Seminars in Oncology 34:4, 321-326
CrossRef356
Giovanni Vitale, Casper H. J. van Eijck, Peter M. van Koetsveld Ing, Joris I. Erdmann, Ernst Jan M. Speel, Katy van der Wansem Ing, Diana M. Mooij, Annamaria Colao, Gaetano Lombardi, Ed Croze, Steven W. J. Lamberts, Leo J. Hofland. (2007) Type I Interferons in the Treatment of Pancreatic Cancer. Annals of Surgery 246:2, 259-268
CrossRef357
Kevin R. Kozak, Lisa A. Kachnic, Judith Adams, Elizabeth M. Crowley, Brian M. Alexander, Harvey J. Mamon, Carlos Fernandez-Del Castillo, David P. Ryan, Thomas F. DeLaney, Theodore S. Hong. (2007) Dosimetric Feasibility of Hypofractionated Proton Radiotherapy for Neoadjuvant Pancreatic Cancer Treatment. International Journal of Radiation Oncology*Biology*Physics 68:5, 1557-1566
CrossRef358
Christopher H. Crane, Gauri Varadhachary, Peter W.T. Pisters, Douglas B. Evans, Robert A. Wolff. (2007) Future Chemoradiation Strategies in Pancreatic Cancer. Seminars in Oncology 34:4, 335-346
CrossRef359
Suresh T. Chari. (2007) Detecting Early Pancreatic Cancer: Problems and Prospects. Seminars in Oncology 34:4, 284-294
CrossRef360
Pascal Hammel. (2007) Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer?. Nature Clinical Practice Oncology 4:8, 460-461
CrossRef361
Hong Chang. (2007) RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research. Cancer Gene Therapy 14:8, 677-685
CrossRef362
Bert H O'Neil, Richard M Goldberg. (2007) Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer?. Nature Clinical Practice Gastroenterology & Hepatology 4:7, 362-363
CrossRef363
Robert G. Maki, Philip O. Livingston, Jonathan J. Lewis, Sylvia Janetzki, David Klimstra, Diann DeSantis, Pramod K. Srivastava, Murray F. Brennan. (2007) A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma. Digestive Diseases and Sciences 52:8, 1964-1972
CrossRef364
Daniel H. Palmer, Deborah D. Stocken, Helen Hewitt, Catherine E. Markham, A. Bassim Hassan, Philip J. Johnson, John A. C. Buckels, Simon R. Bramhall. (2007) A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin. Annals of Surgical Oncology 14:7, 2088-2096
CrossRef365
Stephen A Welch, Malcolm J Moore. (2007) Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncology 3:3, 247-254
CrossRef366
Stephen P. Pereira, Lakshmana Ayaru, Agnieszka Rogowska, Alexander Mosse, Adrian R.W. Hatfield, Stephen G. Bown. (2007) Photodynamic therapy of malignant biliary strictures using meso-tetrahydroxyphenylchlorin. European Journal of Gastroenterology & Hepatology 19:6, 479-485
CrossRef367
Jan Franko, Julia B. Greer, Coleen M. Moran, Asif Khalid, A. James Moser. (2007) Multimodality Therapy for Pancreatic Cancer. Gastroenterology Clinics of North America 36:2, 391-411
CrossRef368
S. Linder, L. Boström, B. Nilsson. (2007) Pancreatic carcinoma incidence and survival in Sweden in 1980–2000: A population-based study of 16,758 hospitalized patients with special reference to different therapies. European Journal of Surgical Oncology (EJSO) 33:5, 616-622
CrossRef369
James P. Neifeld, Stuart McGuire. (2007) Adjuvant therapy for pancreatic cancer: A time that has not yet come. Journal of Surgical Oncology 95:7, 530-531
CrossRef370
Michael Burkitt, Conor Magee, David O'Connor, Fiona Campbell, Philip Cornford, William Greenhalf. (2007) Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition. Molecular Carcinogenesis 46:6, 466-475
CrossRef371
H. Oettle, A. Goerke, P. Vogel. (2007) Pankreaskarzinom. best practice onkologie 2:3, 4-17
CrossRef372
Eugene P. Kennedy, Charles J. Yeo. (2007) The case for routine use of adjuvant therapy in pancreatic cancer. Journal of Surgical Oncology 95:7, 597-603
CrossRef373
A. Zalatnai. (2007) Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma. Cancer Treatment Reviews 33:3, 289-298
CrossRef374
Christopher G. Willett, Brian G. Czito, Johanna C. Bendell. (2007) Adjuvant Therapy of Pancreatic Cancer. The Cancer Journal 13:3, 185-191
CrossRef375
Robert A. Wolff. (2007) Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy. The Cancer Journal 13:3, 175-184
CrossRef376
Jürgen Weitz, Peter Kienle, Jan Schmidt, Helmut Friess, Markus W. Büchler. (2007) Portal Vein Resection for Advanced Pancreatic Head Cancer. Journal of the American College of Surgeons 204:4, 712-716
CrossRef377
Asma Sultana, John Neoptolemos, Paula Ghaneh. (2007) Pancreatic cancer — Adjuvant therapy. The Chinese-German Journal of Clinical Oncology 6:2, 170-175
CrossRef378
J-Matthias Löhr. (2007) Medical treatment of pancreatic cancer. Expert Review of Anticancer Therapy 7:4, 533-544
CrossRef379
Yasuhiro Fujino, Takashi Ueda, Takashi Kamigaki, Shiro Takase, Tetsuo Ajiki, Yasuhisa Kamoda, Ippei Matsumoto, Takeo Yasuda, Yoshikazu Kuroda. (2007) Impact of Gemcitabine on the Survival of Patients With Stage IV Pancreatic Cancer. Pancreas 34:3, 335-339
CrossRef380
Anne Katrin Berger, Drik Jäger. (2007) Pancreatic cancer — Palliative therapy: chemotherapy. The Chinese-German Journal of Clinical Oncology 6:2, 142-148
CrossRef381
R. Krempien, M. W. Munter, W. Harms, J. Debus. (2007) Pancreatic cancer — Neoadjuvant therapy. The Chinese-German Journal of Clinical Oncology 6:2, 162-169
CrossRef382
Yoshiyasu Mita, Tetsuo Ajiki, Takashi Kamigaki, Taro Okazaki, Hiroshige Hori, Hideki Horiuchi, Kenro Hirata, Tsunenori Fujita, Takahiro Fujimori, Yoshikazu Kuroda. (2007) Antitumor Effect of Gemcitabine on Orthotopically Inoculated Human Gallbladder Cancer Cells in Nude Mice. Annals of Surgical Oncology 14:4, 1374-1380
CrossRef383
J. Kleeff, H. Friess, M. W. Büchler. (2007) Neoadjuvant therapy for pancreatic cancer. British Journal of Surgery 94:3, 261-262
CrossRef384
Mary Feng, Edgar Ben-Josef. (2007) Adjuvant therapy for pancreatic cancer: the glass is half empty. Nature Clinical Practice Oncology 4:3, 148-149
CrossRef385
Thomas E. Aloia, Jeffrey E. Lee, Jean-Nicolas Vauthey, Eddie K. Abdalla, Robert A. Wolff, Gauri R. Varadhachary, James L. Abbruzzese, Christopher H. Crane, Douglas B. Evans, Peter W.T. Pisters. (2007) Delayed Recovery after Pancreaticoduodenectomy: A Major Factor Impairing the Delivery of Adjuvant Therapy?. Journal of the American College of Surgeons 204:3, 347-355
CrossRef386
Carlos G. Micames, Frank G. Gress. (2007) Local EUS–guided injection of chemotherapeutic agents as adjuvant to systemic treatment: the first steps are made. Gastrointestinal Endoscopy 65:3, 454-456
CrossRef387
Sandra L. Wong, Yongliang Wei, John D. Birkmeyer. (2007) Use of adjuvant radiotherapy at hospitals with and without on-site radiation services. Cancer 109:4, 796-801
CrossRef388
John D. Spiliotis, Anastasios C. Datsis, Nikolaos V. Michalopoulos, Spyros P. Kekelos, Arhontia Vaxevanidou, Athanasios G. Rogdakis, Athina N. Christopoulou. (2007) Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langenbeck's Archives of Surgery 392:1, 55-60
CrossRef389
Ryuichiro Doi, Kazuhiro Kami, Daisuke Ito, Koji Fujimoto, Yoshiya Kawaguchi, Michihiko Wada, Masafumi Kogire, Ryo Hosotani, Masayuki Imamura, Shinji Uemoto. (2007) Prognostic Implication of Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer. World Journal of Surgery 31:1, 147-154
CrossRef390
Helmut Oettle, Peter Neuhaus. (2007) Adjuvant Therapy in Pancreatic Cancer. Drugs 67:16, 2293-2310
CrossRef391
Gaku Matsumoto, Mariko Muta, Koji Tsuruta, Shinichiro Horiguchi, Katsuyuki Karasawa, Atsutake Okamoto. (2007) Tumor Size Significantly Correlates with Postoperative Liver Metastases and COX-2 Expression in Patients with Resectable Pancreatic Cancer. Pancreatology 7:2-3, 167-173
CrossRef392
Helmut Oettle, Peter Neuhaus. (2007) Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal – The Authors’ Reply. Drugs 67:17, 2491-2493
CrossRef393
Koichi Hirata, Shinichi Egawa, Yasutoshi Kimura, Takayuki Nobuoka, Hidenori Oshima, Tadashi Katsuramaki, Toru Mizuguchi, Tomohisa Furuhata. (2007) Current Status of Surgery for Pancreatic Cancer. Digestive Surgery 24:2, 137-147
CrossRef394
Paula Ghaneh, Catrin Tudur-Smith, John P Neoptolemos. (2007) Comment on “Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal”. Drugs 67:17, 2487-2490
CrossRef395
Stefan Boeck, Donna Pauler Ankerst, Volker Heinemann. (2007) The Role of Adjuvant Chemotherapy for Patients with Resected Pancreatic Cancer: Systematic Review of Randomized Controlled Trials and Meta-Analysis. Oncology 72:5-6, 314-321
CrossRef396
2007. P. , 150-175.
CrossRef397
Ross A Abrams. (2007) Comment on “Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal”. Drugs 67:17, 2481-2485
CrossRef398
Jan Schmidt, Dirk J??ger, Kartin Hoffmann, Markus W. B??chler, Angela M??rten. (2007) Impact of Interferon-?? in Combined Chemoradioimmunotherapy for Pancreatic Adenocarcinoma (CapRI): First Data From the Immunomonitoring. Journal of Immunotherapy 30:1, 108-115
CrossRef399
Shin TAKEDA, Akimasa NAKAO. (2007) Present status of adjuvant chemotherapy for pancreatic cancer. Suizo 22:1, 26-29
CrossRef400
Yasuhiro Fujino, Takashi Ueda, Takashi Kamigaki, Shiro Takase, Tetsuo Ajiki, Yasuhisa Kamoda, Ippei Matsumoto, Takeo Yasuda, Yoshikazu Kuroda. (2007) Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer. Suizo 22:5, 592-594
CrossRef401
H.G. Smeenk, J. Erdmann, H. van Dekken, R. van Marion, W.C.J. Hop, J. Jeekel, C.H.J. van Eijck. (2007) Long-Term Survival after Radical Resection for Pancreatic Head and Ampullary Cancer: A Potential Role for the EGF-R. Digestive Surgery 24:1, 38-45
CrossRef402
Shailesh V. Shrikhande, Jörg Kleeff, Carolin Reiser, Jürgen Weitz, Ulf Hinz, Irene Esposito, Jan Schmidt, Helmut Friess, Markus W. Büchler. (2006) Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology 14:1, 118-127
CrossRef403
Akira Hayashibe, Masao Kameyama, Masaya Shinbo, Shinichiro Makimoto. (2006) Clinical Results on Intra-arterial Adjuvant Chemotherapy for Prevention of Liver Metastasis Following Curative Resection of Pancreatic Cancer. Annals of Surgical Oncology 14:1, 190-194
CrossRef404
Z. Shafaee, H. Schmidt, W. Du, M. Posner, R. Weichselbaum. (2006) Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemotherapy and Pharmacology 58:6, 765-770
CrossRef405
A. Latchford, W. Greenhalf, L. J. Vitone, J. P. Neoptolemos, G. A. Lancaster, R. K. S. Phillips. (2006) Peutz–Jeghers syndrome and screening for pancreatic cancer. British Journal of Surgery 93:12, 1446-1455
CrossRef406
J. Weitz, M. A. Weigand, P. Kienle, D. Jäger, M. W. Büchler, E. Martin. (2006) Stellenwert der Anästhesie in multimodalen onkologischen Therapiekonzepten. Der Anaesthesist 55:12, 1299-1306
CrossRef407
Andrea Formentini, Sylvia Sander, Stephanie Denzer, Joern Straeter, Doris Henne-Bruns, Marko Kornmann. (2006) Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?. International Journal of Colorectal Disease 22:1, 49-55
CrossRef408
Rebekah R. White, Michael W. Kattan, John C. Haney, Bryan M. Clary, Theodore N. Pappas, Douglas S. Tyler, Murray F. Brennan. (2006) Evaluation of Preoperative Therapy for Pancreatic Cancer Using a Prognostic Nomogram. Annals of Surgical Oncology 13:11, 1485-1492
CrossRef409
Florian Eckel, Günter Schneider, Roland M Schmid. (2006) Pancreatic cancer: a review of recent advances. Expert Opinion on Investigational Drugs 15:11, 1395-1410
CrossRef410
PeiHong Jiang, Hiroyuki Watanabe, Gensaku Okada, Koushiro Ohtsubo, Hisatsugu Mouri, Tomoya Tsuchiyama, Fan Yao, Norio Sawabu. (2006) Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Science 97:11, 1267-1273
CrossRef411
Jan Schmidt, Emilia M. Patrut, Jianhua Ma, Dirk Jäger, Hanns-Peter Knaebel, Markus W. Büchler, Angela Märten. (2006) Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunology, Immunotherapy 55:11, 1396-1405
CrossRef412
Knut Jørgen Labori, Marianne Jensen Hjermstad, Torunn Wester, Trond Buanes, Jon Håvard Loge. (2006) Symptom profiles and palliative care in advanced pancreatic cancer—a prospective study. Supportive Care in Cancer 14:11, 1126-1133
CrossRef413
Maurizio Cantore, Giovanni Serio, Paolo Pederzoli, Andrea Mambrini, Calogero Iacono, Coriolano Pulica, Paola Capelli, Mirko Lombardi, Tito Torri, Paola Pacetti, Mauro Pagani, Giammaria Fiorentini. (2006) Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology 58:4, 504-508
CrossRef414
Vicki L. Keedy, Jordan Berlin. (2006) Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer. Current Treatment Options in Oncology 7:5, 381-388
CrossRef415
Thilo Welsch, Jorg Kleeff, Helmut K Seitz, Peter Buchler, Helmut Friess, Markus W Buchler. (2006) Update on pancreatic cancer and alcohol-associated risk. Journal of Gastroenterology and Hepatology 21:s3, S69-S75
CrossRef416
Julia Draznin, Weijing Sun. (2006) Cancers of the bowel and hepatobiliary tract. Update on Cancer Therapeutics 1:3, 353-365
CrossRef417
A W Blackstock, F Mornex, C Partensky, L Descos, L D Case, S A Melin, E A Levine, G Mishra, S A Limentani, L A Kachnic, J E Tepper. (2006) Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. British Journal of Cancer 95:3, 260-265
CrossRef418
Michael C. Garofalo, William F. Regine, Ming T. Tan. (2006) On Statistical Reanalysis, the EORTC Trial Is a Positive Trial for Adjuvant Chemoradiation in Pancreatic Cancer. Annals of Surgery 244:2, 332-333
CrossRef419
Nicolas Carrère, Alain Sauvanet, Diane Goere, Reza Kianmanesh, Marie-Pierre Vullierme, Anne Couvelard, Philippe Ruszniewski, Jacques Belghiti. (2006) Pancreaticoduodenectomy with Mesentericoportal Vein Resection for Adenocarcinoma of the Pancreatic Head. World Journal of Surgery 30:8, 1526-1535
CrossRef420
J??rg Kleeff, Christoph Michalski, Helmut Friess, Markus W. B??chler. (2006) Pancreatic Cancer. Pancreas 33:2, 111-118
CrossRef421
David B Smith, John P Neoptolemos. (2006) Capecitabine in carcinoma of the pancreas. Expert Opinion on Pharmacotherapy 7:12, 1633-1639
CrossRef422
Desmond Yip, Christos Karapetis, Andrew Strickland, Christopher B Steer, David Goldstein, Desmond Yip. 2006. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. .
CrossRef423
William Greenhalf, John P Neoptolemos. (2006) Increasing survival rates of patients with pancreatic cancer by earlier identification. Nature Clinical Practice Oncology 3:7, 346-347
CrossRef424
Xabier de Aretxabala, Ivan Roa, Marcela Berrios, Juan Hepp, Jorge Gallardo, Andres Cordova, Juan Carlos Roa, Jorge Leon, Fernando Maluenda. (2006) Chemoradiotherapy in gallbladder cancer. Journal of Surgical Oncology 93:8, 699-704
CrossRef425
J. M. Löhr, R. Faissner, P. Findeisen, M. Neumaier. (2006) Proteomanalyse. Der Internist 47:S01, S40-S48
CrossRef426
Matthias Löhr. (2006) Is it possible to survive pancreatic cancer?. Nature Clinical Practice Gastroenterology & Hepatology 3:5, 236-237
CrossRef427
Takahiro Einama, Yutaka Kagata, Hitoshi Tsuda, Daisaku Morita, Sho Ogata, Shigeto Ueda, Toshimichi Takigawa, Nobuaki Kawarabayashi, Kazuhiko Fukatsu, Yoshiaki Sugiura, Osamu Matsubara, Kazuo Hatsuse. (2006) High-level Skp2 Expression in Pancreatic Ductal Adenocarcinoma. Pancreas 32:4, 376-381
CrossRef428
J. Tepel, O. Dagvadorj, M. Kapischke, B. Sipos, A. Leins, B. Kremer, H. Kalthoff. (2006) Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. International Journal of Colorectal Disease 21:4, 365-372
CrossRef429
Masaji Tani, Manabu Kawai, Hiroshi Terasawa, Shinomi Ina, Seiko Hirono, Kazuhisa Uchiyama, Hiroki Yamaue. (2006) Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?. Journal of Surgical Oncology 93:6, 485-490
CrossRef430
I Chau, D Cunningham, C Russell, A R Norman, T Kurzawinski, P Harper, P Harrison, G Middleton, F Daniels, T Hickish, J Prendeville, P J Ross, B Theis, R Hull, M Walker, N Shankley, B Kalindjian, G Murray, A Gillbanks, J Black. (2006) Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer 94:8, 1107-1115
CrossRef431
Arthur Y. Hung, Christopher A. Canning, Kamal M. Patel, John M. Holland, Lisa A. Kachnic. (2006) Radiation Therapy for Gastrointestinal Cancer. Hematology/Oncology Clinics of North America 20:2, 287-320
CrossRef432
R. Függer. (2006) Pancreatic carcinoma. European Surgery 38:2, 112-117
CrossRef433
Paula Ghaneh, Asma Sultana, Susannah Shore, Deborah Stocken, John Neoptolemos. (2006) The case for adjuvant chemotherapy in pancreatic cancer. Best Practice & Research Clinical Gastroenterology 20:2, 383-401
CrossRef434
Christopher H. Crane, Gauri Varadhachary, Robert A. Wolff, Peter W.T. Pisters, Douglas B. Evans. (2006) The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Practice & Research Clinical Gastroenterology 20:2, 365-382
CrossRef435
Louis J. Vitone, William Greenhalf, Christopher D. McFaul, Paula Ghaneh, John P. Neoptolemos. (2006) The inherited genetics of pancreatic cancer and prospects for secondary screening. Best Practice & Research Clinical Gastroenterology 20:2, 253-283
CrossRef436
Christoph Oehler, I. Frank Ciernik. (2006) Radiation therapy and combined modality treatment of gastrointestinal carcinomas. Cancer Treatment Reviews 32:2, 119-138
CrossRef437
Michael Garofalo, Todd Flannery, William Regine. (2006) The case for adjuvant chemoradiation for pancreatic cancer. Best Practice & Research Clinical Gastroenterology 20:2, 403-416
CrossRef438
Robert de W. Marsh, Thomas George. (2006) Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Current Gastroenterology Reports 8:2, 111-120
CrossRef439
Mark S. Talamonti, William Small, Mary F. Mulcahy, Jeffrey D. Wayne, Vikram Attaluri, Lisa M. Colletti, Mark M. Zalupski, John P. Hoffman, Gary M. Freedman, Timothy J. Kinsella, Philip A. Philip, Cornelius J. McGinn. (2006) A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma. Annals of Surgical Oncology 13:2, 150-158
CrossRef440
R. Krempien, M. W. Muenter, W. Harms, J. Debus. (2006) Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. HPB: Official Journal of The International Hepato Pancreato Biliary Association 8:1, 22-28
CrossRef441
Andrew M. Lowy. (2006) Putting the Chemo in Chemoradiation for Pancreatic Cancer. Annals of Surgical Oncology 13:2, 135-136
CrossRef442
Koert Kuhlmann, Steve de Castro, Tjarda van Heek, Olivier Busch, Thomas van Gulik, Hugo Obertop, Dirk Gouma. (2006) Microscopically incomplete resection offers acceptable palliation in pancreatic cancer. Surgery 139:2, 188-196
CrossRef443
Kenoki Ohuchida, Kazuhiro Mizumoto, Daisuke Yamada, Kei Fujii, Nami Ishikawa, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, Masao Tanaka. (2006) Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer. International Journal of Cancer 118:2, 405-411
CrossRef444
Anne M. Lewis, Matthew Ough, Juan Du, Ming-Sound Tsao, Larry W. Oberley, Joseph J. Cullen. (2006) Targeting NAD(P)H:Quinone oxidoreductase (NQO1) in pancreatic cancer. Molecular Carcinogenesisn/a-n/a
CrossRef445
Seungmin Bang, Han-Soo Kim, Yee Shin Choo, Seung Woo Park, Jae Bock Chung, Si Young Song. (2006) Differences in Immune Cells Engaged in Cell-Mediated Immunity After Chemotherapy for Far Advanced Pancreatic Cancer. Pancreas 32:1, 29-36
CrossRef446
Stefan Boeck, Petra Stieber, Stefan Holdenrieder, Ralf Wilkowski, Volker Heinemann. (2006) Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. Oncology 70:4, 255-264
CrossRef447
Olaf Horstmann, Heinz Becker. 2006. Pankreas. , 729-775.
CrossRef448
Shahin Sheibani-Rad, Vic Velanovich. (2006) Effects of Depression on the Survival of Pancreatic Adenocarcinoma. Pancreas 32:1, 58-61
CrossRef449
Marco Caricato, Domenico Borzomati, Fabio Ausania, Andrea Garberini, Carla Rabitti, Giuseppe Tonini, Roberto Coppola. (2006) Cerebellar Metastasis from Pancreatic Adenocarcinoma. Pancreatology 6:4, 306-308
CrossRef450
Juergen Tepel, Marie-Luise Kruse, Matthias Kapischke, Sieglinde Haye, Bence Sipos, Bernd Kremer, Holger Kalthoff. (2006) Adjuvant Treatment of Pancreatic Carcinoma in a Clinically Adapted Mouse Resection Model. Pancreatology 6:3, 240-247
CrossRef451
John Hoffman. (2006) Does Prior Adjuvant Chemoradiotherapy Lead to a Safer Pancreatoduodenectomy?. Annals of Surgical Oncology 13:1, 7-9
CrossRef452
Bence Sipos, Motohiro Kojima, Katharina Tiemann, Wolfram Klapper, Marie-Luise Kruse, Holger Kalthoff, Bodo Schniewind, Jürgen Tepel, Herbert Weich, Dontscho Kerjaschki, Günter Klöppel. (2005) Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. The Journal of Pathology 207:3, 301-312
CrossRef453
Malte Buchholz, Mike Braun, Anna Heidenblut, Hans A Kestler, Günter Klöppel, Wolff Schmiegel, Stephan A Hahn, Jutta Lüttges, Thomas M Gress. (2005) Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24:44, 6626-6636
CrossRef454
David C Whitcomb, Asif Khalid, Adam Slivka, Kevin McGrath, A James Moser, Richard H Bell. (2005) Conference Report for APA Postgraduate Course. Pancreas 31:3, 218-220
CrossRef455
Gauri R. Varadhachary, Eric P. Tamm, Christopher Crane, Douglas B. Evans, Robert A. Wolff. (2005) Borderline resectable pancreatic cancer. Current Treatment Options in Gastroenterology 8:5, 377-384
CrossRef456
Dieter Saur, Barbara Seidler, Günter Schneider, Hana Algül, Roswitha Beck, Reingard Senekowitsch–Schmidtke, Markus Schwaiger, Roland M. Schmid. (2005) CXCR4 Expression Increases Liver and Lung Metastasis in a Mouse Model of Pancreatic Cancer. Gastroenterology 129:4, 1237-1250
CrossRef457
Ralph H. Hruban, Marcia I. Canto, Constance Griffin, Scott E. Kern, Alison P. Klein, Dan Laheru, Charles J. Yeo. (2005) Treatment of familial pancreatic cancer and its precursors. Current Treatment Options in Gastroenterology 8:5, 365-375
CrossRef458
Anne M. Lewis, Matthew Ough, Marilyn M. Hinkhouse, Ming-Sound Tsao, Larry W. Oberley, Joseph J. Cullen. (2005) Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Molecular Carcinogenesis 43:4, 215-224
CrossRef459
Vivek Maheshwari, A James Moser. (2005) Current management of locally advanced pancreatic cancer. Nature Clinical Practice Gastroenterology & Hepatology 2:8, 356-364
CrossRef460
Stefan Heinrich, Gerhard W. Goerres, Markus Sch??fer, Markus Sagmeister, Peter Bauerfeind, Bernhard C. Pestalozzi, Thomas F. Hany, Gustav K. von Schulthess, Pierre-Alain Clavien. (2005) Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-Effectiveness. Annals of Surgery 242:2, 235-243
CrossRef461
Moritz N Wente, Anjali Jain, Evelyn Kono, Pascal O Berberat, Thomas Giese, Howard A Reber, Helmut Friess, Markus W B??chler, Robert E Reiter, Oscar J Hines. (2005) Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer. Pancreas 31:2, 119-125
CrossRef462
Mert Erkan, Jörg Kleeff, Irene Esposito, Thomas Giese, Knut Ketterer, Markus W Büchler, Nathalla A Giese, Helmut Friess. (2005) Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24:27, 4421-4432
CrossRef463
G. Chong, D. Cunningham. (2005) Gastrointestinal cancer: recent developments in medical oncology. European Journal of Surgical Oncology (EJSO) 31:5, 453-460
CrossRef464
C Bassi, R Salvia, G Butturini, S Marcucci, G Barugola, M Falconi. (2005) Value of regional lymphadenectomy in pancreatic cancer. HPB: Official Journal of The International Hepato Pancreato Biliary Association 7:2, 87-92
CrossRef465
Lilie L. Lin, Joel Picus, J A. Drebin, David C. Linehan, Juan Solis, Steven M. Strasberg, Benjamin Tan, Wade L. Thorstad, Robert Myerson. (2005) A Phase II Study of Alternating Cycles of Split Course Radiation Therapy and Gemcitabine Chemotherapy for Inoperable Pancreatic or Biliary Tract Carcinoma. American Journal of Clinical Oncology 28:3, 234-241
CrossRef466
Curtis J. Wray, Syed A. Ahmad, Jeffrey B. Matthews, Andrew M. Lowy. (2005) Surgery for Pancreatic Cancer: Recent Controversies and Current Practice. Gastroenterology 128:6, 1626-1641
CrossRef467
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin. (2005) Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. Gastroenterology 128:6, 1642-1654
CrossRef468
François Lacaine. (2005) Evidence-based Medicine in Surgical Decision Making. World Journal of Surgery 29:5, 588-591
CrossRef469
Günter Schneider, Jens T. Siveke, Florian Eckel, Roland M. Schmid. (2005) Pancreatic Cancer: Basic and Clinical Aspects. Gastroenterology 128:6, 1606-1625
CrossRef470
D D Stocken, M W Büchler, C Dervenis, C Bassi, H Jeekel, J H G Klinkenbijl, K E Bakkevold, T Takada, H Amano, J P Neoptolemos. (2005) Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. British Journal of Cancer 92:8, 1372-1381
CrossRef471
A. Junker. (2005) Aktuelle Behandlungsoptionen bei gastrointestinalen Tumoren. Der Onkologe 11:3, 315-319
CrossRef472
S.S. Sikora, P. Balachandran, K. Dimri, N. Rastogi, A. Kumar, R. Saxena, V.K. Kapoor. (2005) Adjuvant chemo-radiotherapy in ampullary cancers. European Journal of Surgical Oncology (EJSO) 31:2, 158-163
CrossRef473
John P Neoptolemos. (2005) Is endoscopic ultrasonography superior to multidetector CT for assessing pancreatic cancer?. Nature Clinical Practice Oncology 2:2, 78-79
CrossRef474
Hans G. Smeenk, Lucca Incrocci, Geert Kazemier, Herman van Dekken, Khe T.C. Tran, Johannes Jeekel, Casper H.J. van Eijck. (2005) Adjuvant 5-FU-Based Chemoradiotherapy for Patients Undergoing R-1/R-2 Resections for Pancreatic Cancer. Digestive Surgery 22:5, 321-328
CrossRef475
D. Lytras, S. Connor, L. Bosonnet, R. Jayan, J. Evans, M. Hughes, C.J. Garvey, P. Ghaneh, R. Sutton, S. Vinjamuri, J.P. Neoptolemos. (2005) Positron Emission Tomography Does Not Add to Computed Tomography for the Diagnosis and Staging of Pancreatic Cancer. Digestive Surgery 22:1-2, 55-62
CrossRef476
Michele Reni, Paolo Passoni, Elisa Bonetto, Gianpaolo Balzano, Maria Grazia Panucci, Alessandro Zerbi, Monica Ronzoni, Carlo Staudacher, Eugenio Villa, Valerio Di Carlo. (2005) Final Results of a Prospective Trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen Followed by Radiotherapy after Curative Surgery for Pancreatic Adenocarcinoma. Oncology 68:2-3, 239-245
CrossRef477
Isao Kurosaki, Katsuyoshi Hatakeyama. (2005) Adjuvant Systemic Chemotherapy with Gemcitabine for Stage IV Pancreatic Cancer: A Preliminary Report of Initial Experience. Chemotherapy 51:6, 305-310
CrossRef478
James E Frampton, Antona J Wagstaff. (2005) Gemcitabine. American Journal of Cancer 4:6, 395-416
CrossRef479
Sherene Loi, Michael Findlay, John Zalcberg. (2005) Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma. American Journal of Cancer 4:3, 159-168
CrossRef480
Sally E. Dowen, Tatjana Crnogorac-Jurcevic, Rathi Gangeswaran, Mikkel Hansen, Jyrki J. Eloranta, Vipul Bhakta, Teresa A. Brentnall, Jutta Lüttges, Gunther Klöppel, Nick R. Lemoine. (2005) Expression of S100P and Its Novel Binding Partner S100PBPR in Early Pancreatic Cancer. The American Journal of Pathology 166:1, 81-92
CrossRef481
Ingemar Ihse, Roland Andersson, Anders Ask, Sven Börje Ewers, Gert Lindell, Karl Göran Tranberg. (2005) Intraoperative Radiotherapy for Patients with Carcinoma of the Pancreas. Pancreatology 5:4-5, 438-442
CrossRef482
Dale Vimalachandran, Eithne Costello. (2004) Proteomic technologies and their application to pancreatic cancer. Expert Review of Proteomics 1:4, 493-501
CrossRef483
B. M. K
nzli, H. Friess, J. Kleeff, E. Yekebas, O. Mann, J. R. Izbicki, M. W. B
CrossRef484
R. Krempien, V. Heinemann, M. M
CrossRef485
S. Connor, L. Bosonnet, P. Ghaneh, N. Alexakis, M. Hartley, F. Campbell, R. Sutton, J. P. Neoptolemos. (2004) Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. British Journal of Surgery 91:12, 1592-1599
CrossRef486
Laureano Fern??ndez-Cruz. (2004) General Surgery as Education, Not Specialization. Annals of Surgery 240:6, 932-938
CrossRef487
S SHORE, D VIMALACHANDRAN, M RARATY, P GHANEH. (2004) Cancer in the elderly: pancreatic cancer. Surgical Oncology 13:4, 201-210
CrossRef488
J. Weitz, M. Koch, J. Kleeff, M. W. M
CrossRef489
N. Alexakis, C. Halloran, M. Raraty, P. Ghaneh, R. Sutton, J. P. Neoptolemos. (2004) Current standards of surgery for pancreatic cancer. British Journal of Surgery 91:11, 1410-1427
CrossRef490
A.A. Sonkar, G.J. Poston. (2004) Adjuvant therapy following surgery for periampullary and pancreatic cancers. European Journal of Surgical Oncology (EJSO) 30:9, 911-912
CrossRef491
Andrea Formentini, Doris Henne-Bruns, Marko Kornmann. (2004) Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbeck's Archives of Surgery 389:5, 405-413
CrossRef492
Harold Frucht, Peter D. Stevens, David R. Fogelman, Elizabeth C. Verna, Johnson Chen, John A. Chabot, Robert L. Fine. (2004) Advances in the genetic screening, work-up, and treatment of pancreatic cancer. Current Treatment Options in Gastroenterology 7:5, 343-354
CrossRef493
D. Goldstein, S. Carroll, M. Apte, G. Keogh. (2004) Modern management of pancreatic carcinoma. Internal Medicine Journal 34:8, 475-481
CrossRef494
(2004) Chemotherapy for Pancreatic Cancer. New England Journal of Medicine 350:26, 2713-2715
Full Text495
Choti, Michael A., . (2004) Adjuvant Therapy for Pancreatic Cancer — The Debate Continues. New England Journal of Medicine 350:12, 1249-1251
Full Text496
Mark Hartel, Moritz N. Wente, Pierluigi Di Sebastiano, Helmut Friess, Markus W. Büchler. (2004) The Role of Extended Resection in Pancreatic Adenocarcinoma: Is There Good Evidence-Based Justification?. Pancreatology 4:6, 561-566
CrossRef497
N.P. Jarufe, C. Coldham, A.D. Mayer, D.F. Mirza, J.A.C. Buckels, S.R. Bramhall. (2004) Favourable Prognostic Factors in a Large UK Experience of Adenocarcinoma of the Head of the Pancreas and Periampullary Region. Digestive Surgery 21:3, 202-209
CrossRef
- Letters
